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Abstract 
Ingrid P. Fricks 
Molecular Pharmacology and Function of the P2Y14 Receptor 
(Under the direction of T. Kendall Harden, Ph.D.) 
 
 P2Y receptors are a family of seven transmembrane spanning G protein-coupled 
receptors that are activated by nucleotides and nucleotide-sugars.  The P2Y14-R is 
activated by nucleotide sugars, although little is known about the physiological role(s) of 
this receptor.  With a view toward generating pharmacological reagents for studies of 
P2Y14-R, one goal of this dissertation was to apply a rational structure-activity 
relationship approach to develop novel ligands for the P2Y14-R.  Guided by molecular 
modeling studies of the P2Y14-R, iterative design of synthetic ligands produced a 
multitude of compounds which were assessed for agonist activity at the P2Y14-R.  From 
these studies, several novel agonists were identified for the P2Y14-R, including 2-thio-
UDP-Glc, which exhibited greater than six-fold higher potency than UDP-Glc.  Other 
novel agonists identified included several UDP-sugars.  Using a COS-7 cell system in 
which recombinant P2Y14-R were co-expressed with the chimeric G protein, Gαq/i, UDP 
was identified as a competitive antagonist at the P2Y14-R.  In contrast, in studies 
comparing the pharmacological selectivity of the rat P2Y14-R to that of the human P2Y14-
R in the same cell system, UDP was found to be an agonist at the rat P2Y14-R.  Another 
goal of this work was to examine the signal transduction pathways downstream of P2Y14-
R activation, and for these studies, stable cell lines expressing P2Y14-R in HEK293 and in 
C6 glioma cells were developed.  This approach allowed study of P2Y14-R coupled to 
native G proteins, and P2Y14-R-dependent inhibition of adenylyl cyclase was observed.  
 iii
P2Y14-R activation also promoted pertussis toxin-sensitive phosphorylation of ERK1/2.  
Moreover, native P2Y14-R were detected in differentiated HL-60 cells by RT-PCR, and in 
these cells, UDP-Glc promoted pertussis toxin-sensitive activation of ERK1/2.  The work 
presented here provides a foundation for future development of pharmacological agents 
for the P2Y14 receptor.  Furthermore, this work establishes that the P2Y14-R couples to Gi 
and the MAP kinase signaling pathway, and provides robust cell model systems for future 
studies of P2Y14-R function.   
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Chapter I.  Introduction 
Nucleotides are important extracellular signaling molecules that activate cell surface 
receptors to regulate many physiological processes such as neurotransmission, 
vasoconstriction/ dilation, cell differentiation, platelet aggregation, and also ion transport in 
epithelial cells.  Previous to Burnstock’s observations in the 1970’s, ATP was generally 
accepted to function only in intracellular processes where it acts as the energy source for the 
cell.  Burnstock originally hypothesized that ATP was released from cells and could act on 
cell surface receptors to contribute to second messenger signaling, based on evidence that 
ATP mediated responses to nerve stimulation independently from cholinergic or adrenergic 
nerve responses (Burnstock, 1972).  We now know that ATP produces autocrine/ paracrine 
signaling in non-excitatory cells as well as functions as an important neurotransmitter, 
involved in a broad range of cellular and organ functions.  Currently, ATP and ADP, as well 
as UTP, UDP, and UDP-glucose are well accepted as extracellular signaling molecules that 
act on a diverse family of nucleotide binding receptors, and extracellular concentrations of 
nucleotides are precisely regulated by cellular release and metabolism by ectoenzymes.   
The following pages will overview the source of extracellular nucleotides and their 
metabolism by ectoenzymes.  Subsequent to discussion of nucleotides present in the 
extracellular space, a general introduction to purinergic receptors will be presented.  A more 
detailed description of members of the P2Y receptor family will follow, with an expanded 
focus on the P2Y14-R, the topic of this dissertation.  
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Cellular release of nucleotides 
Regulated release of ATP through exocytosis from excitatory cells is a phenomenon 
that has been known to occur for many decades.  More recently, nucleotide release from non-
excitatory cells has been established, and evidence for the release of other nucleotides 
including UTP and UDP-glucose has been reported.  Sources for extracellular nucleotides 
include constitutive release from resting cells, release after hormone stimulation or 
mechanical stress, and cell lysis.  Elucidating the mechanism(s) of release is currently the 
topic of investigation in many labs.   
Assays for quantification of ATP have been developed using a luciferase assay, 
allowing spatiotemporal resolution of ATP release and hydrolysis in the medium on cultured 
cells (Dubyak and el-Moatassim, 1993; Taylor et al., 1998; Beigi et al., 1999).  Luciferin is a 
substrate for luciferase, and the catalytic reaction produces luminescence in the presence of 
ATP.  These assays are very sensitive methods for quantification of ATP in the bulk medium 
and have even been adapted to measure cell surface concentrations of ATP with a luciferase 
engineered to be anchored at the plasma membrane (Beigi et al., 1999).  Sensitive assays 
detecting released uridine nucleotides and nucleotide-sugars from cultured cells have been 
developed by Lazarowski and colleagues (Lazarowski et al., 1997a; Lazarowski and Harden, 
1999; Lazarowski et al., 2003).  Such detection assays have informed us about circumstances 
of nucleotide release and also about relative rates of release versus degradation of 
nucleotides.   
Differences in measurements of ATP with soluble luciferase compared with plasma 
membrane-associated luciferase suggest that measurements from the bulk medium are likely 
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to grossly underestimate the concentration at the receptor level (Beigi et al., 1999).  One 
possible explanation for this may be that the microenvironment at the cell surface has a 
higher concentration of nucleotide than is measured in the bulk medium.  That is, higher 
concentrations of nucleotides are retained at the surface of cells in close proximity to cell 
surface receptors, whereas the bulk medium contains a diffused, lower concentration of 
nucleotide due to ectonucleotidase activity.  This may occur because the rates of release and 
accumulation of nucleotide at the cell surface is more rapid than the rate of diffusion 
throughout the bulk medium, or it is possible that hydrolyzing enzymes are localized on the 
cell surface or as soluble enzymes in the medium in an orientation that allows degradation of 
nucleotides away from the site of release and receptor expression, allowing receptors to 
interact with nucleotides immediately upon release before degradation of the nucleotide 
occurs.    
Cellular release of ATP, UTP, or UDP-glucose after mechanical stimulation of cells 
has been well established (Gordon, 1986; Lazarowski et al., 1997a).  Levels of ATP and UTP 
measured in the bulk medium on several types of cultured cells rise sharply within five 
minutes of stimulation.  In contrast to the rapid rise in extracellular concentrations of other 
nucleotides on mechanically stimulated cells, UDP-Glc increases little.  However, UDP-
glucose in the medium on 1321N1 human astrocytoma cells was observed to gradually 
increase to a maximal concentration at 1 h after stimulation of the cells and remain at that 
level for a subsequent 2 h (Lazarowski et al., 2003).  Extracellular UDP-glucose is apparently 
metabolized at a slower rate than ATP in several cell lines and furthermore, the concentration 
reported for UDP-glucose on resting cells was 2-6 fold higher than the ATP concentration, 
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suggesting that UDP-glucose is released constitutively from cells as well as upon mechanical 
stimulation. 
In addition to constitutive release of nucleotides and after mechanical stimulation of 
cells, multiple reports have established that nucleotide release also occurs as a result of 
hormone activation of some GPCRs.  Thrombin treatment of many cell types promotes ATP 
release (Pearson and Gordon, 1979; Joseph et al., 2003), relevant to the work described in 
this dissertation, thrombin promotes UDP-Glc release from astrocytoma cells (Kreda et al., 
2008).  Bradykinin, acetylcholine, and serotonin have all been shown to induce release of 
ATP from several types of cells (Yang et al., 1994; Ostrom et al., 2000; Buxton et al., 2001).  
Hormone activation of cells leads to nucleotide release, and multiple signaling pathways may 
be activated in a cascade from hormone activation and subsequent activation by nucleotides. 
Cell lysis due to tissue damage is another source for extracellular nucleotides.  After 
insults such as ischemia in the brain or heart, nucleotides are released from damaged cells 
and are present at concentrations sufficient to activate P2 receptors (Cook and McCleskey, 
2002; Melani et al., 2005).  Induced ischemia in pig artery increased plasma levels of ATP 
and UTP, and also correlated with vasodilation (Erlinge et al., 2005).  Patients with coronary 
heart disease were found to have higher than normal plasma levels of UTP (Wihlborg et al., 
2006).  Intracellular nucleotides that are released as a course of cell lysis from tissue damage 
are likely to activate nearby P2 receptors.  
The mechanisms for regulated release of nucleotides have not been established.  The 
proposed mechanisms for nucleotide release from epithelial cells are exocytosis of ATP-
containing vesicles, release through ATP-permeable channels, or some combination of these 
two processes.  Observations of ATP-containing vesicles in pancreatic cells support the 
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hypothesis that exocytosis is a mechanism for ATP release (Sorensen and Novak, 2001).  
Additionally, findings from several groups support exocytotic release of ATP as a result of 
cell swelling, and implicate the involvement of phosphatidylinositol-3-kinase (PI3K) (Merlin 
et al., 1996; Feranchak et al., 1999; Gatof et al., 2004).  Several anion channels have been 
reported to be permeable to ATP under certain experimental conditions, although a selective 
ATP channel has not been identified (Wang et al., 1996; Roman et al., 1997; Bell et al., 
2003; Okada et al., 2004).    
Interest in connexin and pannexin hemichannels as potential release mechanisms is 
growing.  Connexins and pannexins have four transmembrane domains with the amino and 
carboxyl termini on the intracellular side of the plasma membrane.  Six subunits (connexons) 
assemble to form hemichannels (Shestopalov and Panchin, 2008).  Connexin hemichannels 
are important components of gap junctions, which allow the flow of ions between cells and 
have even been shown to be permeable to ATP (Penuela et al., 2007).  Pannexins, however, 
do not form gap junctions and furthermore, while they form channels that are permeable to 
ATP, their function has been reported to be inhibited by extracellular ATP (reviewed in 
Dubyak, 2009).  While the exact mechanisms for cellular release of nucleotides remain to be 
elucidated, it seems likely that some combination of vesicular release and channel-regulated 
release are involved in nucleotide release from cells. 
Clearly, metabolism of extracellular nucleotides regulates purinergic receptor 
function.  The specifics of how P2 receptors and ectonucleotidases coordinate physiological 
functions remain largely undefined.  Precise regulation of nucleotide action is likely specific 
to the tissue or cell type and stage of cell development.  Spatiotemporal resolution of 
ectonucleotidase and receptor expression together with accurate measurements of nucleotide 
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concentrations will bring us closer to understanding the biological processes dependent on 
nucleotide signaling. 
Ectonucleotidases 
In addition to release of nucleotides from cells, extracellular concentrations of ATP, 
UTP, ADP, UDP, and UDP-glucose are precisely controlled by cell surface enzymes 
catalyzing nucleotide hydrolysis and phosphorylation (Fig. 1).  Ectoenzymes remove 
nucleotide agonists from the cell surface, contributing an important mechanism for 
terminating P2Y-R signal transduction.  Along with cell surface receptors, most cell types 
also express ecto-nucleoside triphosphate diphosphohydrolases (NTPDases) and other 
enzymes that metabolize nucleotides or interconvert nucleotides.  In addition to 
ectoNTPDases, this cadre of enzymes includes ecto-nucleotide pyrophosphatase 
phosphodiesterase (E-NPP), alkaline phosphatase, adenylate kinase, and nucleoside 
diphosphate kinase (Zimmermann, 2000; Robson et al., 2006) (Fig. 2).  Although some ecto-
enzymes degrade nucleosides in addition to nucleotides, other enzymes that metabolize only 
nucleosides also are expressed on the cell surface, and these include adenosine deaminase, 
purine nucleoside phosphorylase (PNP), and 5’-nucleotidase, which exists as a dimer and is 
anchored to the cell surface through a glycophosphatidylinositol (GPI)-linkage, hydrolyzing 
AMP → Ado + Pi. 
NTPDases  
Of the eight members of the NTPDase family, only NTPDase 1, 2, 3, and 8 are 
expressed at the cell surface, exhibiting an extracellular catalytic site and two transmembrane 
domains.  These four enzymes catalyze nucleotides with a KM in the micromolar range, and 
require divalent cations for their catalytic activity (Kukulski et al., 2005).   
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NTPDase 1/ CD39 hydrolyzes both di- and triphosphate nucleotides to 
monophosphate nucleotides.  Studies investigating the relationship between NTPDase1 and 
P2Y1-R used an engineered fusion protein that expressed NTPDase1 with the P2Y1-R as a 
single construct on CHO cells (Alvarado-Castillo et al., 2002).  The expression of the 
NTPDase in tandem with the receptor caused a shift to the right in the ADP concentration 
effect curve, indicating that ectoenzymes can regulate concentrations of nucleotides with 
physiological consequences.  In previous studies with the P2Y1-R, receptor activation in the 
absence of added agonist was observed.  Basal levels of activation of the P2Y1-R was not 
observed with the fusion protein, suggesting cellular release of nucleotide was autocrinely 
activating receptor.   
While NTPDase1 is expressed mainly in vascular smooth muscle and endothelial 
cells (Enjyoji et al., 1999), it has also been detected in the promyeloid cell line HL-60 and 
increases expression with differentiation of the myeloid leukocyte (Clifford et al., 1997).  
Studies of the NTPDase1/ CD39-/- knockout mouse first implicated this enzyme as an 
important component of platelet biology (Enjyoji et al., 1999), and more recently of other 
physiological processes as well.  Although the knockout mice did not exhibit any gross 
defects in development or viability as compared with wild-type mice, a host of disorders 
have been reported.  Bleeding times in the NTPDase1-/- mice were prolonged (Enjyoji et al., 
1999), suggestive of a deficiency in platelet activation.  This bleeding disorder phenotype 
was rescued following injection of knockout mice with the soluble potato-derived ATPDase 
apyrase.  Likewise, platelets isolated from NTPDase1-/- mice were deficient in their ability to 
aggregate in response to ADP, however the NTPDase1-/- platelets could be activated by ADP 
plus serotonin, suggesting that a Gq-coupled, ADP-activated receptor was desensitized in 
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platelets lacking NTPDase1.  Furthermore, when platelets were treated with apyrase, platelet 
activation in response to ADP was restored, indicating that the P2Y1-R was desensitized with 
chronic agonist stimulation, and NTPDase was necessary for removal of agonist.  Additional 
disorders reported for the NTPDase1-/- mice include impaired neutrophil chemotaxtis 
(Corriden et al., 2008), decreased insulin sensitivity (Enjyoji et al., 2008), and deficiencies in 
microglial migration (Farber et al., 2008), among others.  The broad impact of NTPDase1 
loss in mice indicated that nucleotide/nucleoside signaling has critical roles in many 
biological functions. 
NTPDase2 is expressed on vascular smooth muscle cells as well as on stromal cells 
(Zimmermann, 1999).  NTPDase 2 has a much higher affinity for nucleotide triphosphates 
over diphosphates (Fig. 2).  Studies with NTPDase1 and NTPDase2 highlighted the effects of 
ectoenzyme isotype expression on the observed pharmacological activity of the P2Y1-R 
(Alvarado-Castillo et al., 2005).  When P2Y1-R and NTPDase2 were co-expressed, the EC50 
of ADP was similar to that of P2Y1-R alone.  However, when NTPDase1 was coexpressed 
with the receptor, the ADP curve shifted to the right, likely as a function of ADP hydrolysis 
reducing the available agonist.  In addition to illustrating how ectoenzymes may regulate 
extracellular nucleotide concentrations and thus altering the potency of agonist at a P2Y-R, 
this work also proposed the notion that ectoenzyme expression may indirectly regulate 
receptor expression levels, for example, by inhibiting desensitization of P2Y-R when 
ectoenzymes hydrolyze constitutively-released nucleotides.   
NTPDases 3 and 8 prefer nucleotide triphosphates to diphosphates (Fausther et al., 
2007).  In contrast to the membrane-bound NTPDases (1, 2, 3, and 8), NTPDase5 and 
NTPDase6 are expressed in golgi of monocytes and cardiocytes, respectively, and were 
 9
observed to be secreted from the cell upon heterologous expression.  Both enzymes 
hydrolyze UDP and GDP (Chadwick and Frischauf, 1998; Ivanenkov et al., 2003).  NTPDase 
formation of homo-oligomers has been reported, although it is unclear how oligomerization 
may affect catalytic activity (Grinthal and Guidotti, 2002).   
E-NPPs       
The E-NPP family of enzymes bear a single transmembrane domain with an 
extracellular C-terminus.  The catalytic domain lies in the C-terminal portion of the protein, a 
region that also harbors an EF-hand sequence likely responsible for binding divalent cations 
that are necessary for catalytic activity.  While there exist seven E-NPP enzymes, only three 
isoenzymes in this family hydrolyze nucleotides and dinucleotides.  E-NPPs generally 
recognize a broad array of substrates, including nucleic acids, NAD, lysophospholipids, and 
cAMP.  Furthermore, they can hydrolyze pyrophosphate bonds of nucleotide sugars 
(Zimmermann, 2000).  E-NPP family members are also called PC-1 (E-NPP1), PDNP, and 
autotoxin (E-NPP2).  E-NPP1 can undergo proteolysis causing the C-terminal portion of the 
enzyme to become soluble, a state in which it retains catalytic activity (Belli et al., 1993; 
Clair et al., 1997).  The knockout mouse lacking the E-NPP1 gene develops bone 
abnormalities, indicating that E-NPP1 functions in bone formation biology.  E-NPP2 does 
not have a transmembrane domain, but is secreted from the cell.  E-NPP2 knockout mice are 
embryonic lethal (Yegutkin, 2008), suggesting a critical role in developmental processes.  KM 
values for ENPPs at ATP are in the 50 µM range, similar to that of NTPDases 
(Zimmermann, 2000). 
 
 
 10
Phosphatases and Kinases 
 Other enzymes that are expressed on the cell surface also use nucleotides as 
substrates.  Alkaline phosphatase hydrolyzes tri-, di-, and monophosphate adenine 
nucleotides through cleavage of the terminal phosphate, ultimately yielding nucleoside plus 
inorganic phosphate.  Alkaline phosphatase also cleaves the phosphate group from other 
molecules, such as glucose-phosphate and pyrophosphate (Yegutkin, 2008).  The KM of 
alkaline phosphatase for nucleotides is in the millimolar range.  Alkaline phosphatases can be 
soluble or plasma membrane-associated through a glycophosphatidylinositol (GPI)-linkage 
(Low and Saltiel, 1988; Zimmermann, 2000).  Additionally, nucleoside diphosphokinase 
(NDPK) was identified as a transphosphorylating enzyme that uses ATP to phosphorylate 
UDP or GDP in a reversible reaction, and reciprocally, UTP as substrate will yield ATP + 
UDP (Harden et al., 1997; Lazarowski et al., 1997b; Grobben et al., 1999; Lazarowski et al., 
2000).  The gamma phosphate of the nucleotide triphosphate is cleaved, and subsequently 
used to phosphorylate a nucleotide diphosphate.  Another kinase, adenylyl kinase, converts 
ATP + AMP into 2 ADP molecules (Yegutkin et al., 2002; Picher and Boucher, 2003).    
 Nucleotide concentrations on the extracellular space are a dynamic function of 
cellular release and nucleotide metabolism, which includes degradation, phosphorylation, and 
interconversion.  One could imagine that the differential signaling effects regulated by 
nucleosides and nucleotides are dependent on the nucleotidase isotype expressed on the cell 
surface in addition to the P2Y-R expression.  For example, distinct signal transduction 
pathways are activated by ATP versus ADP versus adenosine, and perhaps the relative ratios 
of nucleotides on the cells are just as critical to physiological homeostasis as is which P2Y-R 
may be expressed on a particular tissue type.    
 11
Purinergic Receptors 
Purinergic signaling encompasses responses initiated by nucleosides and nucleotides.  
P1 receptors define the family of G protein coupled receptors that are activated by adenosine, 
and include the subtypes A1, A2A, A2B, and A3.  P2 receptors are a class of nucleotide-
activated cell surface receptors and are categorized into two families of receptors: P2X 
receptors and P2Y receptors.   
P2X receptors are ligand-gated ion channels, and all are activated by ATP.  The seven 
receptors in the P2X family are: P2X1, P2X2, P2X3, P2X4, P2X5, P2X6, and P2X7.  P2X 
receptors are comprised of three subunits and can exist as homomeric or heteromeric receptor 
assemblies.  When ATP binds, the channel opens, allowing cations to pass through to the 
intracellular space.  P2X1-5,7 are permeable to Na+, K+, and Ca2+ ions.  P2X6 cannot form a 
homomeric receptor, but can form a functional heteromeric receptor with other P2X subunits 
(Ralevic and Burnstock, 1998; Abbracchio et al., 2006).      
 P2Y receptors are metabotropic receptors that couple to heterotrimeric G-proteins.  
There are eight identified P2Y receptors: P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13, and 
P2Y14.  The nomenclature assigned includes numbers up to fourteen, reflecting a repeated 
problem in the field of P2Y receptor research.  The missing P2Y receptor numbers are due to 
receptors that were mistakenly included in this family of receptors.  The receptors that were 
erroneously assigned P2Y numbers have since been re-classified as either non-mammalian 
P2Y orthologs, or belonging to other receptor families, including leukotriene receptors and 
lysophosphatidic acid (LPA) receptors (Yokomizo et al., 1997; Li et al., 1998; Noguchi et al., 
2003). 
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G Protein Signal Transduction 
 P2Y receptors, like other G protein-coupled receptors, couple to heterotrimeric G 
proteins comprised of α, β, and γ subunits.  When agonist binds the cell-surface receptor, 
conformational changes in the receptor coordinate subsequent conformational 
rearrangements in the G protein.  Guanosine 5’-triphosphate (GTP) then replaces guanosine 
5’-diphosphate (GDP) on the Gα subunit and the result is disengagement of the βγ dimer 
from the α subunit.  The GTP-bound Gα is the activated form, and so initiates downstream 
signaling events.  The Gβγ dimer also activates downstream signaling targets such as 
phospholipases, adenylyl cyclases, phosphatidylinositol-3-kinase γ, and ion channels.  
Additional proteins and pathways may also be regulated by Gβγ-dependent signaling, as 
evidenced by the number of Gβγ-binding proteins that have been identified (Smrcka 2008).  
G protein-induced signaling ceases when the intrinsic GTPase activity of the Gα subunit 
causes hydrolysis of GTP to GDP, and the heterotrimeric G protein reassembles.   
The main signaling pathways activated by GPCRs are represented by at least four 
families of heterotrimeric G proteins: Gq, Gs, Gi, and G12.  The Gq family of G proteins 
includes Gαq, Gα11, Gα15, and Gα16, and these subunits activate phospholipase C-β, which 
hydrolyzes phosphatidylinositol 4, 5-bisphosphate (PIP2) into inositol 1, 4, 5-triphosphate 
(IP3) and diacylglycerol (DAG).  IP3 acts on receptors at the endoplasmic reticulum to release 
from its intracellular calcium stores.  DAG activates protein kinase C (PKC).  Gq also has 
been shown to bind to the regulator of G protein signaling (RGS) domain of G protein 
receptor kinase-2 (GRK2) (Carman et al., 1999), and evidence shows that GRK2 is an 
important hub of signaling for the Gq signal transduction pathway, as it binds a number of 
elements in the cascade (Tesmer et al., 2005).  Additionally, guanine nucleotide exchange 
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factors (GEFs) for Rho family proteins interact with Gq.  Rho family proteins are small G 
protein GTPases that control myriad cellular functions such as contraction, motility, and 
proliferation.  At least three Rho GEFs, p63-RhoGEF, Trio, and PDZ-RhoGEF, are known to 
interact with GTP-bound Gq and lead to RhoA activation (Lutz et al., 2005; Rojas et al., 
2007), establishing a link between heterotrimeric G protein signaling and Rho signaling 
pathways. 
The Gs family includes Gαs and the related olfactory system expressed Gαolf.  Gs 
family proteins activate adenylyl cyclase, which generates cyclic adenosine 5’-
monophosphate (cAMP) from ATP.  Protein kinase A (PKA) is downstream of adenylyl 
cyclase and is activated by intracellular cAMP.  Conversely, Gi proteins inhibit some 
isoforms of adenylyl cyclase (I, III, V, VI, and VIII) and also regulate ion channels (Gilman, 
1987; Birnbaumer, 1992; Clapham and Neer, 1997), which appears to be through released 
Gβγ subunits.  The Gi family is comprised of Gαi1, Gαi2, Gαi3, Gαo, Gαt, Gαz, and Gαgust.  
Tissue-specific expression was established for Gαt in the retina, Gαgust in the gustatory 
system, and Gαz in platelets and brain.   
G12 family proteins (Gα12, Gα13) are ubiquitously expressed.  G12 proteins activate 
guanine nucleotide exchange factors (GEFs) for RhoA family members such as PDZ-
RhoGEF, p115RhoGEF, and leukemia-associated RhoGEF (LARG) (Kozasa et al., 1998; 
Suzuki et al., 2003).  G12 G proteins may also interact with other signaling molecules such 
as cadherins, protein phosphatases, and non-receptor tyrosine kinases to modulate other 
signaling pathways.  Studies of mouse models suggest that the functions of Gα12 and Gα13 are 
distinct.  Gα13-/- mice do not survive more than a few days, while Gα12-/- mice survive into 
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adulthood, suggesting differential roles for G12 proteins in developmental processes 
(Offermanns et al., 1997).   
Termination of agonist-promoted GPCR signaling occurs when G protein receptor 
kinases (GRK) phosphorylate residues on intracellular domains of the receptor.  This acts as 
a signal for β-arrestin recruitment to the plasma membrane, where it uncouples GPCR from 
G proteins.  Arrestins also mediate internalization of some GPCRs, acting as a scaffold for 
the receptor with endocytosis machinery.  Endocytosed receptors may be either recycled to 
the plasma membrane, or degraded via the lysosome (Krupnick and Benovic, 1998).     
P2Y Receptors 
P2Y receptors are grouped into two categories based on amino acid sequence 
homology and proposed G-protein coupling selectivity (Fig. 3).  The P2Y1-R subgroup 
includes P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11, all of which couple to Gαq and lead to 
activation of PLC.  The P2Y11 receptor also couples to Gαs to increase intracellular cAMP.  
The P2Y12-R subgroup is comprised of P2Y12, P2Y13, and P2Y14, all of which are proposed 
to couple to Gαi to inhibit formation of cAMP (Abbracchio et al., 2006).  GPR87, an orphan 
receptor, exhibits high amino acid sequence homology to the P2Y14-R, (Schoneberg et al., 
2007), suggesting that GPR87 likely shares a common ancestor with the P2Y12-like P2Y-R.  
However, GPR87 was recently reported to be activated by lysophosphatidic acid (LPA) 
(Tabata et al., 2007).   
The P2Y1 receptor is activated by ADP.  The P2Y2 receptor is activated by UTP and 
ATP, while the human P2Y4 receptor is activated only by UTP.  The only receptor known to 
be activated by UDP is the P2Y6 receptor.  The P2Y11 receptor is activated by ATP.  In the 
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P2Y12-R subgroup, both P2Y12 and P2Y13 receptors are activated by ADP, and the P2Y14 
receptor is activated by UDP-glucose and other nucleotide-sugars. 
While the lack of selective, high affinity antagonists has impeded research on P2Y 
receptors, several labs have ongoing studies to identify competitive antagonists at each of the 
P2Y receptors, and progress has been greatest for the P2Y1-R and P2Y12-R.  In fact, a 
prodrug, clopidogrel, that metabolizes into a P2Y12-R antagonist, is used therapeutically to 
prevent thrombosis (Foster et al., 2001; Hollopeter et al., 2001).  Antagonists for the P2Y2, 
P2Y6, P2Y11, and P2Y13 receptors have been described and can be used as templates for the 
development of high affinity compounds that will be useful for pharmacological studies of 
P2Y receptors (Jacobson et al., 2008).  Although ATP is an antagonist at the human P2Y4-R 
(Herold et al., 2004), no selective antagonists have been identified for the P2Y4 and P2Y14 
receptors.  Several non-selective acting antagonists for P2Y receptors have been identified.  
These include PPADS, suramin, and reactive blue 2 (Ralevic and Burnstock, 1998; Brown 
and Brown, 2002).  
P2Y1-like Receptors 
P2Y1-R 
 The P2Y1 and P2Y12 receptors have a well established function in platelet biology 
(Dubyak et al., 1993; Savi et al., 1998; Hechler et al., 1998a; Leon et al., 1999; Fabre et al., 
1999).  The role of ADP in platelet aggregation involves both the Gq-activating P2Y1-R as 
well as the Gi-activating P2Y12-R.  Knockout mice for P2Y1-R exhibited increased bleeding 
time after tail amputation as compared with wild-type mice.  Platelets from these mice lost 
the ability to undergo shape change in response to ADP.  However, platelets treated with 
ADP retained the capacity to inhibit adenylyl cyclase (Fabre et al., 1999).  Although the 
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P2Y1-R is one element of the platelet clotting response to injury, the P2Y12-R governs the 
aggregation component of platelet activation only after Gq-dependent shape change has 
occurred (Enjyoji et al., 1999; Bourdon et al., 2006). Pharmacological studies using P2Y1-R-
selective ligands in human platelets revealed that the P2Y1-R undergoes rapid desensitization 
upon activation (Bourdon et al., 2006).   
P2Y2-R 
 The P2Y2-R has been reported to have an important role in ion secretion and 
absorption in airway epithelial cells.  Upon activation of P2Y2-R by UTP or ATP, Cl- 
secretion increases and Na+ absorption is inhibited.  Improvement of mucociliary clearance 
in cystic fibrosis patients was demonstrated after treatment with inhaled P2Y2 receptor 
agonists (Kellerman et al., 2002).  In the P2Y2-R knockout mouse, the effect of UTP on 
inositol phosphate levels and calcium mobilization in tracheal and nasal epithelial cells was 
abrogated.  Likewise, UTP- and ATP-dependent Cl- transport was disrupted in trachea from 
the P2Y2-R-/- mouse (Cressman et al., 1999; Homolya et al., 1999). Additionally, multiple 
studies have identified P2Y2-R mRNA in immune cells, where ATP and UTP effects have 
been reported (Chen et al., 2006; Myrtek and Idzko, 2007).  Moreover, the P2Y2-R is 
implicated in atherosclerosis (Seye et al., 2002), suggesting that P2Y2-R may have a role in 
inflammation processes.  In rats overexpressing the P2Y2-R, lesions were observed on their 
lacrimal glands, which regulate fluid secretion to the eyes, and also on the kidney by 3 
months of age (Agca et al, 2008), supporting the notion that P2Y2-R also regulates fluid 
secretion in the eye and kidney. 
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P2Y4-R 
The P2Y4-R is activated by UTP.  ATP acts as an antagonist at the human P2Y4-R, 
and it was determined also to be an agonist at the rat ortholog receptor (Kennedy et al., 
2000).  In humans, P2Y4-R are expressed in brain, intestine, lung, liver, and placenta 
(Communi et al., 1995).  Chloride secretion in the epithelium of the small and large intestines 
is dependent on P2Y4-R activation, as determined by studies with P2Y4-R knockout mice 
(Robaye et al., 2003; Ghanem et al., 2005).  Just as the P2Y2-R is important for chloride 
secretion in lung, the P2Y4-R is likely the primary P2Y-R involved in chloride secretion in 
intestine. 
P2Y6-R 
 UDP-activated P2Y6-R are expressed throughout the body, specifically in heart, lung, 
spleen, and intestine, as well as in monocyte-derived immune cells (Communi et al., 1996).  
Recently, cooperative signal transduction of the P2Y6-R with the cysteinyl leukotriene 
receptor CysLT1R was reported in human mast cells, such that when one receptor was 
inhibited via shRNA technology or with the use of a selective antagonist, the other receptor 
also lost its function (Jiang et al., 2009).  Although the relevance of such an effect is 
unknown, the overlapping receptor expression distribution and the possibility that the two 
signal transduction pathways are linked suggest that the P2Y6-R may have an important role 
in innate immune responses.  While the physiological function of P2Y6-R is unknown, 
reports of UDP-dependent phagocytosis in rat microglia and upregulation of P2Y6-R mRNA 
72 h after neuronal damage suggest an immunoprotective role for P2Y6-R (Koizumi et al., 
2007).  A recently developed knockout mouse for the P2Y6-R strongly supports the role of 
P2Y6-R in immune responses (Bar et al., 2008).  While no obvious abnormalities were 
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observed on the P2Y6-R-/- mouse, macrophages isolated from the mouse lacked UDP-
promoted signal transduction and cytokine production.  Additional studies with the P2Y6-R 
knockout mouse suggested that P2Y6-R may regulate vasoconstriction in aorta in response to 
UDP treatment.  The P2Y6-R was recently reported to be involved in the induction of cardiac 
fibrosis through G12/13 signaling to Rho in mice (Nishida et al., 2008), prompting further 
investigation of the P2Y6-R as a potential therapeutic target for heart disease.  
P2Y11-R 
P2Y11-R mRNA has been detected in placenta, brain, and lymphocytes (Communi et 
al., 1997; Moore et al., 2001).  Unique among the P2Y receptors, the P2Y11-R gene has 
several introns (Communi et al., 2001b).  Another distinctive characteristic of the P2Y11-R is 
that it couples to both Gq to activate PLC as well as to Gs to activate adenylyl cyclase (Qi et 
al., 2001).  Additionally, species-specific pharmacological differences have been identified 
for the P2Y11-R.  While ADP may be a weak partial agonist at the human P2Y11-R, ADP acts 
as a potent full agonist at the canine P2Y11-R (Qi et al., 2001).  ATP was reported to induce 
differentiation of HL-60 cells into neutrophil-like cells, and conventional inducers of 
differentiation such as DMSO and dibutyryl-cAMP increased the mRNA expression of 
P2Y11-R.  The P2Y11-R has been implicated for involvement in maturation and migration of 
dendritic cells (Wilkin et al., 2001; Marteau et al., 2004; Idzko et al., 2007).  Taken together, 
it appears that the P2Y11-R may be involved in hematopoiesis. 
P2Y12-like receptors  
The three P2Y receptors in the P2Y12-R subgroup share amino acid sequence 
homology of approximately 44%.  The P2Y12-like receptor genes are clustered on 
chromosome 3, at 3q24-25 (Nomura et al., 1994).  Evolution of the P2Y12-R family has been 
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fairly conserved across species.  The P2Y12-like receptors are found in almost all vertebrate 
classes, and have not been identified in non-vertebrates (Schoneberg et al., 2007).  In some 
fishes and amphibians, orthologous receptors share close homology to two receptors from the 
P2Y12-like subgroup.  For example, one ortholog is related to P2Y12/13 and another is related 
to P2Y14/GPR87, suggesting a point of evolutionary distinction for these receptors. 
P2Y12-R 
The P2Y12-R is the most investigated of the subgroup due to its clinical relevance in 
anti-blood clotting therapeutics.  Evidence for a critical physiological role of the P2Y12-R in 
aggregation of platelets is well-accepted.  Knockout mice lacking the P2Y12-R exhibited 
prolonged bleeding times (Foster et al, 2001).  Platelets from P2Y12-R-/- mice responded to 
ADP with shape change as did the platelets from wild-type mice.  However, platelets lacking 
P2Y12-R did not aggregate and further analysis revealed they did not inhibit adenylyl cyclase 
in response to ADP.  Studies with the knockout mouse underscore the role of the P2Y12-R as 
a critical component in platelet biology.  Antithrombotic therapeutics successfully interrupt 
platelet aggregation in response to P2Y-R signaling, as evidenced by the widely-prescribed 
drug clopidogrel, an active metabolite of which acts as an irrevesible P2Y12-R antagonist 
(Quinn and Fitzgerald, 1999; Gachet, 2005; Savi and Herbert, 2005).   
In addition to platelets, P2Y12-R are expressed throughout brain and in smooth 
muscle cells (Burnstock and Knight, 2004).  The importance of the P2Y12-R in microglial 
response to tissue injury was highlighted by a study comparing wild-type mice to P2Y12-R-/- 
mice (Haynes et al., 2006).  The P2Y12-R was detected at the protein and RNA levels 
expressed on microglia.  Wild-type microglial cultures, but not those from P2Y12-R-/- mice, 
responded to ADP with lamelipodial extensions.  Furthermore, chemotaxis of P2Y12-R-
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expressing cells toward an ADP gradient was demonstrated with microglial cultures, and 
process extension and migration of microglia were observed in response to laser-induced 
tissue damage in living mice, but were significantly delayed in P2Y12-R-/- mice.  This study 
and others define the P2Y12-R as a crucial element in microglial development and response to 
injury (Davalos et al., 2005).  
P2Y13-R 
  The P2Y13-R is similar to the P2Y12-R in amino acid sequence, in G protein coupling, 
and in agonist profile.  The P2Y13-R also couples to ERK1/2 activation in CHO-K1 cells.  In 
contrast to the P2Y12-R, expression of the P2Y13-R is reported in spleen, small intestine, 
liver, kidney, brain, and on peripheral immune cells (Communi et al., 2001a; Fumagalli et al., 
2004; Wang et al., 2004), but the physiological significance of the P2Y13-R has not yet been 
examined.  An analogue of PPADS, MRS2211, recently has been described as a selective, 
competitive antagonist at the P2Y13-R (Wirkner et al., 2004; Kim et al., 2005).    
P2Y14-R 
 The P2Y14-R is the eighth member of the P2Y receptor family.  It shares 44% amino 
acid sequence homology to the P2Y12-R and P2Y13-R, compared to only 22% with the P2Y1-
R; it is accordingly grouped into the P2Y12-like receptor sub-family.  The intronless P2Y14-R 
gene encodes 338 amino acids (Fig. 5).  While the P2Y14-R was first cloned from the human 
myeloid cell line KG-1 (Nomura et al., 1994) and relatively high levels of P2Y14-R mRNA 
have been detected in neutrophils, expression of the P2Y14-R has also been reported in the 
brain, lung, stomach, heart, placenta, and adipose tissue (Moore et al., 2003).  Although a 
functional role for the P2Y14-R has not yet been identified, evidence suggests that one 
function of the receptor may be contributing to immune system homeostasis.    
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P2Y14-R Tissue Distribution 
There have been several antibodies generated to recognize the P2Y14-R, although 
none has been fully characterized.  For example, a commercially available antibody is 
reported to recognize the second extracellular loop of the receptor, a region that is conserved 
in mouse and rat sequences (Alomone, Jerusalem, Israel).  This antibody was used to detect 
expression of glycosylated P2Y14-R in glioma C6 cells (Krzeminski et al., 2008), and the 
authors reported that non-glycosylated receptor became predominantly expressed upon serum 
starvation of the cells.  However, results discussed in Chapter 4 of this dissertation 
contradicts the expression of P2Y14-R in C6 glioma cells.  Another P2Y14-R antibody was 
generated against the first extracellular loop of the receptor (Lee et al., 2003) and was used to 
detect expression of the P2Y14-R on human fetal bone marrow cells.  Additionally, an 
antibody against the C-terminus of the P2Y14-R was generated for immunohistochemical 
studies in which  P2Y14-R expression was reported throughout the brain, but only in sub-
populations of glial cells (Moore et al., 2003).  The specificity of these antibodies is 
unknown because results for recognition of other P2Y-R or of non-specific immunoreactivity 
in each experimental system were not reported.  Until the usefulness of these antibodies has 
been validated, we still lack reliable means for detecting P2Y14-R directly. 
 In their report of glial P2Y14-R expression, Moore and colleagues also used RT-PCR 
to demonstrate the presence of P2Y14-R transcripts in neutrophils, lymphocytes, and also in 
the leukocyte cell lines M-07e and UT7-Epo, as well as in HEK293 cells (Moore et al., 
2003).  The P2Y14-R message has been detected in platelets (Moore et al., 2003; Dovlatova et 
al., 2008).  However, the receptor has not been shown to be functional in such cells.  Other 
reports of tissue distribution based on RT-PCR studies include highest levels in placental and 
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adipose tissue, and also in stomach, intestine, lung, and heart (Chambers et al., 2000).  
Reports of P2Y14-R mRNA upregulation in mouse uterus after estradiol treatment for seven 
days (Crabtree et al., 2006; Crabtree et al., 2008) suggest that P2Y14-R expression may be 
regulated by circulating hormone levels.  
 Other reports of P2Y14-R expression include microglia and astrocytes (Charlton et al., 
1997), non-neuronal spinal cord cells (Kobayashi et al., 2006), and synoviocytes from human 
patients suffering from rheumatoid arthritis (Caporali et al., 2008), which together may 
indicate a neuroprotective role for the P2Y14-R. 
Regulation of the P2Y14-R 
Expression and function of GPCRs are dynamically regulated through several 
mechanisms, from post-translational modifications, cellular localization and cell-stage-
dependent expression to signaling events and internalization regulated by motifs and domains 
harbored within the receptor’s sequence.  Although little is known about the regulation of the 
P2Y14-R, we can surmise that it has many potential mechanisms for regulation based on what 
is known of other GPCRs and shared sequence characteristics of the P2Y14-R. 
Like other GPCRs, the P2Y14-R exhibits several distinctive amino acid sequence 
characteristics.  At the intracellular region of transmembrane 3, the sequence includes the 
residues aspartate-arginine-tyrosine.  This “DRY motif” is highly conserved among seven 
transmembrane GPCRs.  In other GPCRs, these residues are suspected to interact with acidic 
residues in the third intracellular loop and such interactions are thought to regulate receptor 
activation (Ballesteros et al., 2001).  However, the P2Y14-R does not have any acidic residues 
in the third intracellular loop, and 30% of seven transmembrane GPCRs, including all of the 
known chemokine receptors, do not exhibit an acidic residue at the expected point of 
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interaction.  In fact, the P2Y14-R sequence in the third intracellular loop is rich in positively 
charged residues, so the significance of the DRY motif in this receptor may be different from 
other GPCRs.  Additionally, GPCRs are known to exhibit two conserved cysteine residues in 
the extracellular domains that form disulfide bonds for stabilizing the receptor’s tertiary 
structure.  Indeed, the P2Y14-R has a cysteine residue in each of the four extracellular 
domains.  The P2Y14-R also exhibits potential consensus sequences for phosphorylation by 
protein kinase A (PKA) and protein kinase C (PKC) in its third intracellular loop, but there is 
no evidence available that either of these protein kinases interact with this receptor. 
Similar to all other P2Y-R, potential N-glycosylation sites occur on extracellular 
domains of the P2Y14-R.  Glycosylation of the receptor was reported to modulate its function 
(Krzeminski et al., 2008).  Indeed, the glycosylation state of the P2Y12-R has also been 
reported to bear functional consequences (Zhong et al., 2004).  While glycosylation of 
GPCRs is thought to be important for insertion into the lipid bilayer, it is possible that the 
glycosylation state has an impact on receptor expression or otherwise promotes a 
conformational orientation of the receptor that compromises ligand binding or G-protein 
coupling or activation.  However, it remains to be determined whether glycosylation is an 
important mechanism for regulating the P2Y14-R.   
Cellular localization of the receptor may also be an important means for regulating 
receptor function.  Confocal microscopy studies of HA-epitope tagged P2Y14-R suggest that 
the receptor localizes to the basolateral membrane of polarized epithelial cells (Wolff et al., 
2005).  In light of the reported P2Y14-R expression in lung and and in immune cells, it is 
possible that the P2Y14-R has a specific function related to its basolateral localization in cells.  
The P2Y2-R, for example, exhibits apical localization in lung epithelial cell lines (Qi et al., 
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2005; Wolff et al., 2005), and has been demonstrated to be important in mucociliary 
clearance (Cressman et al., 1999; Donaldson et al., 2000). 
Desensitization is an important mechanism for GPCRs to terminate receptor signaling 
in the presence of chronic agonist exposure.  Because it has been demonstrated that UDP-Glc 
is released from cells constitutively as well as after mechanical and pharmacological 
stimulation, it is likely that UDP-Glc is constantly present in the extracellular space.  
Therefore, the question arises whether the P2Y14-R desensitizes and how this may impact 
UDP-Glc-dependent signal transduction.  Other P2Y-R are regulated by desensitization, and 
exhibit various rates of desensitization upon agonist stimulation.  The P2Y6-R, for example is 
reported to desensitize after prolonged agonist stimulation (Brinson and Harden, 2001), while 
the P2Y1-R and P2Y12-R desensitize quickly in platelets after agonist activation leads to 
shape change and aggregation (Hardy et al., 2005; Bourdon et al., 2006).  Future studies will 
determine whether desensitization plays a role in P2Y14-R-dependent processes.         
 As we gain insight into the functional role of the P2Y14-R, we will undoubtedly learn 
more about how this receptor is regulated.  Myriad mechanisms have been demonstrated for 
regulation of other P2Y receptor functions, and the significance of amino acid sequence 
signals, post-translational modifications and desensitization on P2Y14-R function will await 
further investigation. 
Pharmacology and Signal Transduction 
UDP-Glc has long been known as a compound that is concentrated in the ER/Golgi 
apparatus and is a component of the protein synthesis quality control machinery (Parodi, 
2000).  With the discovery that the P2Y14-R is activated by UDP-Glc and three other UDP-
sugars (Fig. 5), the notion of nucleotide-sugars as extracellular signaling molecules was 
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introduced.  The rank order of potency of P2Y14-R agonists has been reported as follows:  
UDP-glucose ≥ UDP-galactose ≥ UDP-glucuronic acid > UDP-N-acetylglucosamine 
(Chambers et al., 2000).  While UDP-Glc is considered the endogenous agonist, the other 
UDP-sugars have been reported to have varying degrees of efficacy at the P2Y14 receptor.  
There have not been any reports of antagonists for this receptor.    
UDP-Glc promoted GTPγS binding on HEK293 membranes expressing recombinant 
P2Y14-R.  Additionally, UDP-Glc promoted calcium mobilization when the P2Y14-R was co-
expressed with the promiscuous Gα16 (Chambers et al., 2000).  The P2Y14-R also couples to 
the chimeric Gαq/i (Lazarowski et al., 2003; Moore et al., 2003).  This chimeric G protein is a 
Gq that has been engineered to couple Gi-coupled receptors to PLC (Coward et al., 1999).  
The P2Y14-R is expected to couple to Gαi leading to inhibition of adenylyl cyclase, but this 
has yet to be shown. 
In some experimental systems, investigators have observed UDP-Glc-dependent Ca2+ 
mobilization, indicating that the P2Y14-R may couple to PLCβ isoforms, likely through 
release of Gβγ upon activation of Gi.  UDP-glucose- and UDP-galactose-dependent increases 
in Ca2+ in rat cortical astrocytes were reported (Fumagalli et al., 2003).  UDP-Glc-dependent 
increases in Ca2+ were also observed in human immature dendritic cells (Skelton et al., 
2003).       
Physiological Significance 
  While the physiological role of the P2Y14-R remains unclear, the reportedly high 
expression levels in leukocytes in conjunction with several reports of UDP-Glc-dependent 
activity in immune response assays suggests that there may be a potential role for the P2Y14-
R in immune system homeostasis.  P2Y14-R mRNA was demonstrated to be upregulated in 
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rat brain after immunologic challenge with lipopolysaccharide (Moore et al., 2003), 
suggesting that the P2Y14-R may be involved in immune responses to bacterial insult, as LPS 
treatment has been shown to modulate release of cytokines and upregulate expression of 
chemokine receptors (Palin et al., 2001; Banisadr et al., 2002).  P2Y14-R mRNA has also 
been detected in immature human dendritic cells, which are immune cells that mature and 
migrate to a site of inflammation in response to insult or injury (Skelton et al., 2003).  UDP-
Glc affected a calcium response in immature dendritic cells, suggesting that the P2Y14-R may 
have a role in induction of maturation of dendritic cells in response to high concentrations of 
ligand released from injured tissues.  Furthermore, Scrivens and Dickenson (2005, 2006) 
reported P2Y14-R expression in T-lymphocytes from mice and in human neutrophils, and 
reported UDP-Glc-, but not other UDP-sugar-dependent inhibition of adenylyl cyclase 
stimulation in both cell types (Scrivens and Dickenson, 2005; Scrivens and Dickenson, 
2006).  In T-lymphocytes, the authors reported that all four UDP-sugar agonists partially 
inhibited IL-2- and anti-CD3-induced cell proliferation, suggesting that perhaps the P2Y14-R 
is involved in T-lymphocyte biology.  The authors observed no P2Y14-R-dependent effect on 
elastase release, which is an assay for neutrophil degranulation.  While it seems likely there 
will be a role for the P2Y14-R in immune response physiology, it is too early to speculate on 
details related to which cell processes may be modulated by P2Y14-R function. 
Aims of this dissertation 
The work presented in the following pages addresses specific aims of research 
regarding molecular pharmacology and signal transduction of the P2Y14-R.  In Chapter 2, 
studies to develop novel ligands for the P2Y14-R will be discussed.  Rhodopsin-based 
homology modeling was used to simulate theoretical interactions of known P2Y14-R agonists 
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with the receptor.  Analyses revealed the putative involvement of several residues interacting 
with the hexose moiety, suggesting that the glucose structure may be an important part of the 
molecule for receptor activation.  For these studies, a cellular assay system was developed 
that employs the chimera Gαq/i and over-expressed P2Y14-R in COS-7 cells.  Novel, selective 
ligands for the P2Y14-R have been developed based on structure-activity relationships, and 
we are continuing in this endeavor to identify high affinity agonists and antagonists that can 
be used as templates to propel the development of pharmacological research tools for the 
P2Y14-R.  A specifically acting ligand will augment the currently available methods for 
studying the P2Y14-R and distinguishing its individual physiological role relative to other 
P2Y receptors.   
In Chapter 3, the identification of a competitive antagonist for the P2Y14-R in a 
heterologous system is reported.  Few selective antagonists are available for any of the P2Y 
receptors, causing difficulties in conclusive establishment of a physiological role for 
individual receptor subtypes.  The lack of selective antagonists for the P2Y14-R has impeded 
investigation into the signaling properties and tissue distribution of this receptor.  The 
identification of UDP as an antagonist at the P2Y14-R contributes to our knowledge of P2Y14-
R pharmacology and will further our work toward developing a high affinity, non-
hydrolyzable competitive antagonist for the receptor. 
An additional element of Chapter 3 includes an investigation into the molecular 
pharmacology of the rat ortholog of the P2Y14-R, and a comparison of known ligands to 
determine whether the rat P2Y14-R functions similarly to the human receptor.  Precedence for 
divergent pharmacological activation profiles among species orthologs has been reported for 
the P2Y4-R and for the P2Y11-R.  The studies presented in Chapter 3 reveal differences in the 
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pharmacological profile between the human and rat P2Y14-R and will be necessary criteria 
for assessing studies of the P2Y14-R in murine model systems.  
Chapter 4 details the findings that the P2Y14-R couples to inhibition of adenylyl 
cyclase and activates ERK1/2.  One goal of these studies was to generate stable cell lines for 
examining P2Y14-R signal transduction through its natively coupling G protein.  Studies 
performed in HEK293 epithelial cells and in C6 rat glioma cells have established that the 
P2Y14-R couples to the Gi family of G proteins.  Furthermore, the identification of a 
functional P2Y14-R endogenously expressed in differentiated HL-60 cells provides a system 
for examining this receptor at expression levels and with signal transduction pathways that 
are likely to be similar to its native physiological activity.  While P2Y14-R expression has 
been reported in various tissues and brain regions, we are still far from understanding the 
physiological role of this receptor, and have barely begun to uncover the signaling networks 
downstream of receptor activation.  With no explicit pathophysiologies in mouse or man to 
hint at potential functions for this receptor, model cell systems will be critical for furthering 
our knowledge of signal transduction and biological responses from P2Y14-R activation. 
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Figure 1.  Nucleotides are released from cells and are metabolized by ectoenzymes.  
ATP, UTP, and UDP-Glc undergo regulated release from cells via an unknown mechanism.  
Extracellular nucleotides and nucleotide-sugars are metabolized by plasma membrane-
anchored enzymes such as E-NPPs and NTPDases.  Nucleotide triphosphates are degraded 
into nucleotide diphosphates, and subsequently into nucleotide monophosphates.  UDP-Glc is 
metabolized by E-NPP family of ectoenzymes, resulting in UMP and glucose-1-P. 
 30
 
 31
 
 
Figure 3.  P2Y-R agonists and G protein coupling schematic.  The metabotropic P2Y 
receptor family is comprised of eight members and is divided into two subfamilies, P2Y1-
like and P2Y12-like, based on amino acid sequence homology and proposed G-protein 
coupling.  P2Y1-R, P2Y2-R, P2Y4-R, P2Y6-R, and P2Y11-R activate Gq, and P2Y11-R also 
activates Gs.  P2Y12-R, P2Y13-R, and P2Y14-R activate Gi.  P2Y-R are activated by 
nucleotides and nucleotide sugars. 
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Figure 4.  P2Y14-R serpentine model.  The P2Y14-R has 338 amino acids with seven 
predicted transmembrane domains.  The P2Y14-R exhibits protein sequence features common 
to other P2Y-R, such as potential N-glycosylation sites at the amino-terminal region, four 
extracellular cysteine residues that are predicted to form 2 disulfide bridges, and 
aspartate118-arginine119-tyrosine120 form a “DRY motif” at the intracellular cusp of 
transmembrane 3.    
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Figure 5.  The P2Y14-R is activated by UDP-sugars.  Four agonists possessing similar 
chemical structures have been identified.  Compared with UDP-glucose, UDP-galactose  
has an inverted chirality of the hydroxyl group at position 4 of the hexose ring.   
UDP-glucuronic acid has a carboxylic acid substituted for the hydroxyl group in  
UDP-glucose at position 6 of the hexose ring.  UDP-N-acetylglucosamine exhibits a  
bulky acetamide group at position 2 of the hexose ring in comparison with the  
hydroxyl group of UDP-glucose.  
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Chapter II.  Identification of P2Y14-R ligands using structure-activity 
relationships and molecular modeling 
Introduction 
The diverse family of P2Y-R are widely distributed and have emerged as therapeutic 
targets for several pathophysiologies (Volonte et al., 2006).  The P2Y1-R and P2Y12-R play a 
vital role in platelet activation, and a metabolite of the drug clopidogrel, clinically used as an 
antithrombotic, is an irreversible antagonist at the P2Y12-R (Foster et al., 2001; Hollopeter et 
al., 2001).  Also, the P2Y2-R is an essential regulator of chloride transport in lung and other 
tissues.  In cystic fibrosis patients, the P2Y2-R is a therapeutic target for improvement of 
mucociliary clearance (Kellerman et al., 2002).  Although evidence for P2Y-R involvement 
in a number of physiological processes is robust, research on this receptor family has been 
impeded by the lack of selectively acting pharmacological agents.  Further complicated by 
cellular release of nucleotides and the metabolism of extracellular nucleotides, 
characterization of P2Y-R has relied primarily on studies of recombinant receptors and 
detection of receptor mRNA in tissues.    
Detection of P2Y receptors has been primarily based on quantification of mRNA due 
to the lack of reliable radioligand binding assays.  Because levels of mRNA expression do 
not always equate to levels of expressed protein, studies attributing receptor function to 
presence of mRNA must be interpreted cautiously.  Additionally, reports of species-specific 
pharmacological profiles for P2Y-R underscore the necessity to validate findings from 
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animal models in human tissues as well.  For example, ATP was demonstrated to be an 
antagonist at the human P2Y4-R and an agonist at the rat P2Y4-R (Kennedy et al., 2000).     
Ectonucleotidases are expressed on the cell surface, and they metabolize agonist for 
some P2Y-R subtypes even while generating agonist for another.  Extracellular nucleotide 
concentrations are dependent on expression of ectonucleotidases, thus impacting the potency 
for a particular nucleotide at a given receptor.  The expression of different types of 
ectoenzymes on the cell surface may selectively permit the activation of a subset of P2Y-R 
due to the availability of each nucleotide.  Another inherent challenge to studies of P2Y 
receptors is that nucleotides are released from cells upon mechanical stimulation, with 
changes in the pH of cell growth medium, after hormone stimulation of cells, and upon cell 
lysis (Fitz, 2007).   
Commercial preparations of nucleotides with a high level of purity are sometimes 
difficult to obtain.  ATP that is contaminated with UTP, for example, would produce 
confounding results in studies of multiple P2Y receptors.  When uridine nucleotide receptors 
were first cloned, the selectivities of the agonists were only clarified when contaminating 
UTP was converted to UDP with the use of hexokinase (Nicholas et al., 1996).  Likewise, 
ATP that has degraded into ADP would complicate studies of receptors targeted by ATP, or 
mislead the investigator to believe that ATP has an effect at ADP-activated receptors.  A 
study investigating P2Y14-R function in N9 microglial cells describes different effects of 
UDP-Glc depending on the source of the material, underscoring potential technical 
complications that may occur due to contaminated compounds purchased commercially 
(Brautigam et al., 2008).      
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 Novel P2Y receptor ligands exhibiting high affinity and receptor selectivity have 
been developed with the use of high throughput screens, receptor mutagenesis studies, 
structure-activity relationships (SAR), and molecular modeling (Jacobson et al., 2008).  High 
throughput screening has been limited in its usefulness for identifying P2Y receptor ligands, 
but in contrast, molecular modeling has recently become an effective method in conjunction 
with activity studies to guide development of new structural compounds. 
 Ligand development studies have identified novel agonists and antagonists for the 
P2Y2-R, P2Y6-R, and the P2Y12-R. Greatest progress has been realized, however, with ligand 
development for the P2Y1-R.  The finding that the adenosine bisphosphate molecules 
(A3P5PS) and (A3P5P) are competitive antagonists at the P2Y1-R was the impetus for 
launching a series of studies to develop high affinity antagonists for the P2Y1-R (Boyer et al., 
1996).  These compounds were used in studies to delineate the role of the P2Y1-R in platelet 
biology and also to distinguish the effects of the P2Y12-R from those of the P2Y1-R in signal 
transduction leading to platelet activation (Hechler et al., 1998; Jin et al., 1998).  These 
bisphosphate molecules were not ideal P2Y-R ligands because of their low affinity for the 
P2Y1-R and their structure was easily metabolized by ectoenzymes, so molecular modeling 
of the P2Y1-R in conjunction with SAR studies produced synthetic ligands with more 
desirable properties, using A3P5P as a template.  A selective and higher affinity antagonist, 
N6-methyl 2'-deoxyadenosine 3',5'-bisphosphate (N6MABP), also known as MRS2179, was 
developed subsequently, although it also was vulnerable to hydrolysis (Boyer et al., 1998).  
MRS2179 was widely used in studies characterizing the P2Y1-R in platelets and in 
astrocytes.  [33P]MRS2179 was used for quantifying P2Y1-R in platelets, verifying P2Y1-R 
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function in platelets, and MRS2179 also was assessed for its effects on platelet aggregation 
when systemically administered to mice (Baurand et al., 2001). 
 Following success with MRS2179, ligand development studies for the P2Y1-R 
became focused on non-hydrolyzable ligands that retained selectivity and high affinity at the 
receptor.  A constrained bicyclo-hexane ring moiety was introduced in place of the ribose, 
and through molecular modeling studies, the Northern (N) conformation of the ring was 
found to be tolerated at the P2Y1-R.  One of the molecules that emerged from these studies, 
2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine 3',5'-bis-phosphate, also called 
MRS2279, was the first non-nucleotide competitive antagonist at the P2Y1-R that was widely 
used for characterization of the P2Y1-R without agonist degradation (Boyer et al., 2002).  
[3H]MRS2279 was used in radioligand binding assays to quantify P2Y1-R expression on 
various types of cells (Waldo et al., 2002).  An analogous molecule with a 2-iodo 
substitution, MRS2500, exhibited an affinity at the P2Y1-R of 1 nM, ten-fold higher than that 
of MRS2279 (Kim et al., 2003).  With the development of [32P]MRS2500, distribution of the 
P2Y1-R was quantified in rat tissues and also in human platelets (Houston et al., 2006). 
 In addition to the development of high affinity competitive antagonists, development 
of high affinity selective agonists for the P2Y1-R has also met with success.  Upon 
determination of the high affinity and hydrolysis-resistant properties conferred by the (N)-
methanocarba modification in antagonists, (N)-methanocarba-2-methylthio-ADP (MRS2365) 
was developed as a high affinity non-nucleotide agonist for the P2Y1-R that was inactive at 
the ADP-activated P2Y12-R and P2Y13-R (Chhatriwala et al., 2004).  These newest synthetic 
ligands for the P2Y1-R will prove useful in further studies of P2Y1-R function not only in 
platelets, but also in other tissues expressing functional P2Y1-R.   
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 Propelled by successes with ligand development for the P2Y1-R, we have applied a 
similar rational SAR approach to discovery of high affinity ligands for the P2Y14-R.  
Characterization of the P2Y14-R has been primarily based on RNA-level receptor expression 
and also with studies reporting biological consequences of extracellular UDP-Glc treatment 
on cultured cells, but has been impaired by the lack of high affinity agonists and competitive 
antagonists.  What we know of P2Y14-R function and tissue expression in native tissues is 
limited, and could benefit from the development of non-hydrolyzable, selective, high affinity 
ligands.   
The P2Y14-R was first described as a UDP-glucose receptor after the receptor was 
cloned and expressed in a heterologous cell system, and screened against multiple potential 
agonists (Chambers et al., 2000).  In addition to UDP-glucose, three other UDP-sugars were 
identified as agonists at the P2Y14-R: UDP-galactose, UDP-glucuronic acid, and UDP-N-
acetylglucosamine.  This initial discovery provided the framework for a series of studies in a 
collaboration between our lab and the lab of Dr. Kenneth A. Jacobson at the National 
Institutes of Health.  The goal of this work is to develop selective, high affinity agonists and 
antagonists for the P2Y14-R.  Molecular modeling studies have guided syntheses of UDP-Glc 
analogues examined for agonist action at the P2Y14-R.  These studies have been published 
(Ivanov et al., 2007; Ko et al., 2007; Ko et al., 2009), and will be reviewed herein. 
Methods 
Cell Culture.  COS-7 cells were grown on 12-well culture dishes and maintained in DMEM 
supplemented with 10% FBS and 4 mM L-glutamine at 37°C in a 10% CO2 environment.  
Cells were transfected 48 h prior to assay with pcDNA3.1 expression vectors encoding the 
human P2Y14 receptor.  Transfections also included a pcDNA3.1-Gαq/i, a vector that directs 
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expression of a chimera of Gq containing the last five amino acids of Gi.  This chimeric G 
protein promotes activation of phospholipase C through Gi-coupled receptors (Coward et al., 
1999).  The levels of basal inositol phosphates increase markedly in COS-7 cells upon 
expression of human P2Y14-R and Gαq/i.  Since we have previously shown that this activity is 
dependent on release of cellular UDP-sugars (Lazarowski et al., 2003), in some experiments 
pcDNA3.1 expressing ectonucleotide pyrophosphatase/ phosphodiesterase-1 (ENPP1) was 
co-transfected with the goal of lowering basal inositol phosphate signaling and therefore 
increasing fold response to the agonist.  FuGENE 6 (Roche Applied Science, Indianapolis, 
IN) was used as the transfection reagent following the manufacturer’s protocol. 
Inositol Phosphate Accumulation Assay.  Cells were labeled 18 h prior to assay with 1 µCi/ 
well [3H]-myo-inositol (American Radiolabeled Chemicals, St. Louis, MO) in inositol-free 
and serum-free DMEM.  The assay was started with the addition of 10 mM LiCl with or 
without drugs and cells were incubated for 45 min at 37°C.  The reaction was stopped by 
aspiration of medium and addition of ice-cold 50 mM formic acid.  After neutralization with 
150 mM ammonium hydroxide, [3H]inositol phosphates were isolated by Dowex column 
chromatography as described previously (Nakahata and Harden, 1987).   
Summary of Results 
The P2Y14-R was subjected to rhodopsin-based homology modeling to estimate an 
overall structure for the receptor, and UDP-Glc was modeled into the putative binding pocket 
of the P2Y14-R to predict points of contact in the ligand-receptor complex.  From these 
studies, extrapolations regarding regions of the pharmacophore that would tolerate 
modifications as well as enhance potency at the receptor were made.  Structural analogs of 
UDP-Glc were synthesized and pharmacologically assessed at recombinant P2Y14-R.  The 
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receptor was co-expressed with a chimeric Gq/i in COS-7 cells.  Gq/i is an engineered 
chimeric construct that replaces the five carboxyl terminal residues of Gq with those of Gi 
(Coward et al., 1999).  Thus, P2Y14-R were artificially coupled to PLC activation, and 
measurement of P2Y14-R function was accomplished by quantifying accumulated 
[3H]inositol phosphates. 
Structure of the P2Y14-R by molecular modeling 
When all of the P2Y receptors were modeled to rhodopsin, general interpretations 
were made regarding similarities and differences among P2Y receptors.  All of the P2Y 
receptors, including P2Y14-R have intermolecular hydrogen bonds among the transmembrane 
regions that help to stabilize the protein: TM1 – TM7; TM3 – TM6, TM7; TM2 – TM4.  
Specific differences in the binding sites between P2Y1-like and P2Y12-like receptors were 
also identified (Costanzi et al., 2004). 
The initial modeling study of the P2Y-R used rhodopsin as a template and built a 
homology model of the P2Y14-R (Costanzi et al., 2004).  Homology modeling is a useful tool 
to estimate the three dimensional orientation of a protein, and can provide information about 
intermolecular interactions and putative ligand binding sites.  The modeling study of the 
P2Y14-R was refined by molecular dynamics simulation, and furthermore, UDP-Glc was 
used in studies to identify the ligand binding site on the P2Y14-R by automatic molecular 
docking to the P2Y14-R model and then Monte Carlo Multiple Minimum (MCMM) analyses 
were performed (Ivanov et al., 2007; Ko et al., 2007).     
   The molecular dynamic simulation revealed that the first extracellular loop and the 
third intracellular loop exhibited the greatest flexibility in the molecule, while the second 
extracellular loop exhibited virtually no movement.  The constrained nature of the second 
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extracellular loop was verified with the identification of multiple interactions among residues 
in that region of the protein.  Hydrogen bonds can form between Arg165 and Glu166, and 
also between Arg165 and Lys176.  Arg165 is also in proximity to Glu12 in the N-terminal 
region, suggesting a potential interaction between these two residues.  Other potential 
interactions between EL2 residues and other regions of the receptor include hydrogen bonds 
between Glu174 and Arg253, and also between Glu166 and Lys277. 
When UDP-Glc was docked into the putative binding site of the P2Y14-R model, 
multiple potential points of interaction between ligand and receptor were identified (Fig. 6).  
The two possible conformations of the ribose ring (Northern versus Southern) of UDP-Glc 
were compared to determine which may be favored.  In modeling studies of other P2Y-R-
ligand complexes, the Northern (N) conformation of the ribose ring was preferred, with the 
exception of the P2Y6-R (Kim et al., 2002).  The 3’-hydroxyl group of the ribose ring of 
UDP-Glc did not form hydrogen bonds with the receptor in either (N)-UDP-Glc or (S)-UDP-
Glc.  The 2’-hydroxyl group, however, formed hydrogen bonds with different residues in 
each of the conformations.  With (N)-UDP-Glc, the 2’-hydroxyl group formed a hydrogen 
bond with Asn104.  In contrast, the 2’-hydroxyl group of (S)-UDP-Glc formed a hydrogen 
bond with Asn287.  The modeling studies indicated that either of the conformations of UDP-
Glc may be tolerated, and this hypothesis was probed experimentally with UDP-Glc 
containing a carbocyclic analogue of the ribose, a methanocarba ring, and results of which 
will be discussed below.  
The uracil ring of UDP-Glc was in close proximity to several residues, suggesting 
potential interactions between ligand and receptor at these points (Fig. 6).  Tyr29 is a highly 
conserved residue among P2Y receptors, and has been identified as a residue that may 
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interact with the uracil moiety in other P2Y-R (Costanzi et al., 2004).  Likewise, it may also 
be important in ligand binding at the P2Y14-R, as the oxygen atom at position 4 of the uracil 
ring in UDP-Glc was close to Tyr29 in the P2Y14-R model.  Additional interactions are 
predicted to occur between the oxygen atom at position 2 of the uracil ring with Asn287 
and/or Val288.  Other potentially important interactions for receptor binding to the uracil 
moiety may be between the 3-NH group of uracil and Val32 and Val288. 
The phosphate groups of UDP-Glc were also analyzed for potential interactions with 
the P2Y14-R (Fig. 6).  The α-phosphate of UDP-Glc associated with the hydroxyl groups of 
Ser284 and with residue Thr280, which is highly conserved among P2Y-R.  Another 
proposed receptor interaction with the phosphate chain of UDP-Glc is with Lys171, which is 
located in the second extracellular loop of the P2Y14-R.  Other P2Y12-like receptors also have 
been proposed to interact with the ligand phosphate chain at an EL2 lysine.  However, other 
proposed interactions between the phosphate chain and residues in TM6 and TM7 in the 
P2Y12-like receptors do not appear to be critical for phosphate group interactions with the 
P2Y14-R.  The hexose moiety of UDP-Glc is predicted to form many hydrogen bonds with 
residues in the P2Y14-R, most of which are located in the second extracellular loop and 
transmembrane regions (Fig. 6).  Hydroxyl groups on the hexose ring likely form hydrogen 
bonds with one or more of the following residues when the P2Y14-R binds UDP-Glc:  
Arg253 (TM6), Lys277 (TM7), Lys171 (EL2), Glu174 (EL2), and Glu166 (EL2).      
Other UDP-sugars that are known agonists were used in modeling studies of the 
P2Y14-R (Ko et al., 2009).  UDP-galactose, UDP-glucuronic acid, and UDP-N-
acetylglucosamine are all similar in structure to UDP-glucose except at the sugar moiety 
(Table 1).  UDP-galactose has a hydroxyl group at position 4 of the hexose ring like UDP-
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glucose, but the hydroxyl group has an inverted chirality.  UDP-glucuronic acid is like UDP-
glucose except that there is a carboxylic acid group at position 6 of the hexose, while UDP-
glucose has only a hydroxyl group at that position.  UDP-N-acetylglucosamine is the least 
like the other UDP-sugars.  At the 2 position of the hexose ring, UDP-Glc has a hydroxyl 
group, but UDP-N-acetylglucosamine has a bulky acetamide group.  UDP-N-
acetylglucosamine has been observed to exhibit the least potency of the four UDP-sugars at 
the P2Y14-R (Table 1), and molecular modeling may give us an idea as to why that may be 
true.  When each of the UDP-sugars was docked into the P2Y14-R model, they all assumed a 
relatively similar position to UDP-Glc in the putative binding site and were proposed to 
maintain most of the hydrogen bonds observed for UDP-Glc.  However, in the case of UDP-
N-acetylglucosamine, the bulky acetamide group did not appear to form any interactions with 
the receptor and caused a slight shift in the orientation of the receptor in that region.  While it 
is not clear whether an altered receptor orientation is responsible for the lower potency of 
UDP-N-acetylglucosamine at the P2Y14-R, it is likely that the acetamide group at position 2 
of the hexose ring is responsible for steric occlusion of the receptor binding site.  Further 
docking studies substituted other sugar moieties for glucose in an attempt to guide design of 
novel agonists at the P2Y14-R.   
 Molecular modeling studies of the P2Y14-R were informative with regard to 
identifying the putative ligand binding site of the receptor and assisted in predictions of 
receptor conformation within the lipid bilayer and potential intermolecular interactions.  
These studies revealed that the hexose moiety of UDP-Glc appears to be the most flexible 
region of the molecule for purposes of synthesizing novel ligands for the P2Y14-R, and this 
prediction is well supported by results from biological assays as described below.    
 56
Structure-Activity Relationships of UDP-glucose analogs at the P2Y14-R 
a. Uracil and Ribose Modifications 
Most of the modifications made to UDP-glucose on the uracil or ribose rings yielded an 
inactive molecule at the P2Y14-R (Table 2).  Specifically, substitution of the uracil moiety 
with the other bases cytidine, guanine, or adenine produced a compound with no effect.  
Modifications at the 5-position of the uracil ring (iodo-, azido-, amino-) of UDP-Glc 
abolished agonist activity.  Two uracil modifications were tolerated.  A 4-thio substitution on 
the uracil ring retained agonist activity and 4-thio-UDP-Glc was equipotent to UDP-Glc (Fig. 
7A).  A methylated thio group at the same position was not tolerated, resulting in a 
compound with no effect.  A thio substitution at the 2 position, 2-thio-UDP-Glc, resulted in a 
compound that exhibited at least six-fold greater potency than UDP-Glc (Fig. 7B). 
 More than a dozen ribose-modified compounds were synthesized.  These modifications 
included 2’- and 3’-deoxy compounds, substitutions at varying positions on the ring, and 
replacement of the ribose with a rigid methanocarba moiety, in either the Southern or 
Northern conformation.  All of the ribose modified compounds had no effect at the P2Y14-R 
(Table 2), indicating that this part of the molecule is important for maintaining stability of the 
ligand-receptor complex.  Additionally, UMP, UDP, UTP, and several dinucleotides were 
tested for agonist activity, and no effect of any of these compounds was observed.  From 
these results we have determined that modifications to the ribose moiety of UDP-Glc are not 
tolerated, and while more permissive, few modifications to the uracil ring are tolerated that 
retain agonist activity at the P2Y14-R.  This restrictive SAR of the P2Y14-R is in sharp 
contrast to that of other P2Y receptors, since modifications to the base or ribose moieties 
were mostly tolerated and retained efficacy, although not necessarily potency.      
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b. Hexose Modifications 
Informed by molecular modeling studies of the P2Y14-R in complex with various 
potential ligands, compounds with substitutions at the glucose ring were synthesized and 
tested as novel ligands.  Generally, substitutions of other sugars for glucose were well 
tolerated (Table 3).  UDP-fructose, UDP-mannose, and UDP-inositol were identified as novel 
agonists at the P2Y14-R with potencies similar to that of UDP-Glc.  Additional sugar 
substitutions were made to synthesize UDP-arabinose, UDP-fucose, and UDP-ribose, which 
all retained activity at the P2Y14-R.  Thus, it appears that most simple sugar substitutions are 
tolerated in place of the hexose position and exhibit agonist action at the P2Y14-R. 
It is clear that chirality of the hydroxyl groups on the hexose ring is critical in ligand 
recognition.  UDP-galactose is structurally similar to UDP-Glc.  However, the inverted 
chirality of the hydroxyl group at position 4 slightly reduces the potency of UDP-galactose at 
the P2Y14-R (Table 1).  Similarly, while a chiral inversion at position 1 of the hexose ring, 
UDP-β-glucose, decreased the potency of UDP-Glc at the P2Y14-R only two-fold, an inverted 
chirality of the hydroxyl group at position 2 resulted in UDP-mannose, a compound with 
three-fold lower potency than UDP-Glc (Table 3).       
More in depth studies were undertaken to probe the pharmacophore with particular 
consideration to the hexose moiety.  Fluoro-substitutions for the hydroxyl moieties at each of 
the hexose ring positions revealed reduced potencies upon fluoro substitution at the 2’ and 6’ 
positions, likely destablilizing the receptor-ligand complex due to the loss of a hydrogen 
bond.  The importance of the hydrogen bond at the 2’ position was further demonstrated by 
the observations that inversion of the 2’-hydroxyl chirality reduced the potency of UDP-Glc 
at the P2Y14-R, and 2’-deoxy-UDP-Glc exhibited greatly reduced efficacy (Table 3).  
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To explore the possibility of attaching a bulky chain onto a P2Y14-R ligand, a functional 
congener approach was employed (Li et al., 1999).  An amide-linked chain was attached to 
the carboxylic acid moiety of UDP-glucuronic acid.  As was predicted from modeling 
studies, these UDP-glucuronic acid analogues exhibited agonist activity at the P2Y14-R with 
similar potencies compared to UDP-glucuronic acid (Table 3).  We concluded that position 6 
of the hexose moiety is a tractable portion of the pharmacophore, and thus, it may be possible 
to conjugate large molecules to a P2Y14-R agonist through a carefully-placed functional 
group without losing affinity for the receptor. These findings provide an opportunity to 
synthesize new P2Y14-R ligands with bulky chemical groups, compounds which may be 
utilized in pharmacological studies.  Fluorophore-conjugated ligands that are selective for the 
P2Y14-R would be useful in characterizing receptor expression in tissues and cells.  Likewise, 
attachment of probes that increase affinity or selectivity for the receptor would provide a 
useful tool for quantifying and further characterizing the P2Y14-R in various tissues. 
Conclusions  
 Molecular modeling functions as a rational starting point to guide objectives of ligand 
structure-activity relationship studies for the purpose of developing novel ligands for the 
P2Y14-R.  Molecular modeling has predicted UDP-Glc contact sites at the uracil, phosphate, 
and hexose moieties.  The SAR studies, however, expanded our understanding of the nature 
of those interactions with regard to the role of each putative contact point in stabilizing the 
receptor-ligand complex.  Furthermore, studies of UDP-Glc analogues informed us about 
how modifications at each part of the molecule impacts potency at the receptor.  The second 
extracellular loop of the P2Y14-R appears to play an important role in stabilizing the hexose 
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moiety of the UDP-Glc molecule, and transmembrane domains three, six, and seven also 
harbor contact points for the phosphate and uracil moieties. 
 Agonist binding pockets of other P2Y receptors have also been predicted to form 
among residues in the TM3, TM6, TM7, and the EL2 (Costanzi et al., 2004), although 
different orientations of agonist in each receptor’s binding pocket dictates the particular 
residues that are important for agonist binding for each receptor.  Evidence from comparisons 
modeling ADP in the binding sites of the P2Y1-R or the P2Y12-R suggests that the same 
agonist uses non-correlative residues in each of the distinctive binding pockets.  While 44% 
shared sequence homology between the P2Y14-R and the P2Y12-R may ostensibly indicate 
closely aligned binding sites, differences in ligand selectivity undoubtedly make differences 
in binding modes necessary.  Comparisons to previous modeling studies with the P2Y12-R 
and P2Y13-R suggest that the P2Y14-R uses some analogous residues – an arginine in TM6, a 
lysine in TM7, and another lysine in EL2 - in forming a binding pocket.  These studies are 
ongoing, and as we learn more about the structure of the P2Y14-R and its ligand selectivity, 
we can pursue further the development of high affinity ligands for use in characterizing 
P2Y14-R function and expression.    
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Table 1. P2Y14-R agonists.  Table of P2Y14-R agonists previously identified with 
corresponding EC50 values measured by phosphatidylinositol hydrolysis assays in COS-7 
cells.  Left, structure of UDP-sugars, and R denotes the sugar substitution shown in the table. 
 
 
 
 HO2C 
OH 
O
N
H O
OP
O
O H
H N
O
O
O H
OP
O
O H
R
0.370 ± 0.070 UDP-glucuronic 
acid 
4.38 ± 1.05 UDP-N-Ac-glucosamine 
0.670 ± 0.090 UDP-galactose
0.261 ± 0.053 UDP-glucose
O O
OHHO
OH
OH
O O
HO
OH
O O
OHHO
OH
OH
O O
NHCOCH3HO
OH
OH
Agonist  R         EC50, µM ± SE 
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Table 2. Ribose and uracil modifications on UDP-Glc are largely inactive at the P2Y14-
R.  Compounds assessed for agonist activity at the P2Y14-R include ribose-modified, base-
modified, ribose- and base-modified UDP-Glc analogues, and also dinucleotides.  EC50 
values reported are derived from phosphatidylinositol hydrolysis assays in COS-7 cells 
transiently expressing the P2Y14-R and Gq/i as described in Methods. (NE= no effect at 10 
μM) 
 
Modification EC50 at  
hP2Y14 receptor, µM ± SE 
Ribose modified 
2′-deoxy 
 
NE 
2′-deoxy-2′-azido 
 
NE 
2′-deoxy-2′-amino 
 
NE 
cyclic-2′- 
deoxy-2′-aminocarbonyl-3′-O 
 
NE 
3′-deoxy 
 
NE 
2′,3′-dideoxy-2′-methoxy-carbonyl 
 
NE 
2′-fluoro-2′-deoxyara NE 
(S)-methanocarba NE 
(N)-methanocarba NE 
(S)-mc-2′-deoxy 
 
NE 
carbocyclic NE 
Base-modified 
4-thio 
 
0.29 ± 0.16 
4-methylthio 
 
>10 
2-thio 
 
0.049 ± 0.02 
5-iodo 
 
NE 
5-azido 
 
NE 
5-amino NE 
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Base = C 
 
NE 
Base = A 
 
NE 
Base = G 
 
NE 
N4-methoxy-CDP-glucose <50% max at 10 µM 
Ribose- and Base-modified 
2′-deoxy-C 
 
NE 
2′-deoxy-T 
 
NE 
2′-deoxy- 
5-F-U 
 
NE 
Dinucleotides   
Up2U 
 
NE 
Cp2C 
 
NE 
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Table 3. Modifications at the hexose moiety of UDP-Glc are largely tolerated as agonists 
at the P2Y14-R. All of the simple sugars substituted for the glucose moiety retain agonist 
activity at the P2Y14-R, most with similar potency as UDP-Glc.  EC50 values were 
determined from phosphatidylinositol assays in COS-7 cells transiently expressing the 
P2Y14-R.  2’-Substitutions or deletion of the hydroxyl group reduce potency or efficacy.  
Functional congener substitutions are the last two compounds in the table.   Inset, structure of 
UDP-sugar, and R denotes the hexose substitution shown in the table. 
 
 
 
Modification Structure 
R = 
EC50 at  
hP2Y14 receptor, µM ± SE 
UDP-β-[1]glucose 
 
0.588 ± 0.130 
UDP-[1]mannose 
O O
OHHO
OH
OH
 
0.910 ± 0.150 
UDP-[1]fucose 
 
0.562 ± 0.173 
UDP-N-Ac-galactosamine 
O O
NHCOCH3HO
OH
OH
 
0.810 ± 0.090 
O
N
H O
OP
O
O H
H N
O
O
O H
OP
O
O H
R
O O
OHHO
CH3
OH
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UDP-2΄-F-[1]glucose 
 
2.5 ± 0.9 
UDP-3΄-F-[1]glucose 
O O
OHHO
F
OH
 
0.361 ± 0.094 
UDP-4΄-F-[1]glucose 
 
0.567 ± 0.156 
UDP-6΄-F-[1]glucose 
 
0.905 ± 0.429 
UDP-[6]glucose 
 
0.373 ± 0.073 
UDP-[6]mannose 
 
0.658 ± 0.022 
UDP-[6]2΄-deoxyglucose 
 
<50% max at 10 µM 
UDP-[5]ribose 
 
0.238 ± 0.084 
UDP-[5]arabinose 
 
0.460 ± 0.057 
OHO
HO OH
OH
O
OHO
HO OH
OH
O
OHO
OH
OH
O
O
OH
O
HO
HO
O
OH
O
HO
HO
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UDP-[1]fructose 
 
0.880 ± 0.210 
UDP-[6]fructose 
 
0.323 ± 0.069 
UDP-inositol 
 
 
1.88 ± 1.10 
UDP-[2-(acetylamino)-2-deoxy α-D-
glucopyranosyl] methyl phosphonyl 
uridine 5΄yl phosphate 
 
<50% max at 10 µM  
UDP-glucuronyl-ED-Ac  0.496 ± 0.067 
UDP-glucuronyl-ED-Boc  0.951 ± 0.277 
 
 
O
HO
HO
OH
OH
O
O
OH
O
HO
HO
HO
O
OHHO
HO
OH
OH
O O
OHHO
C
OH
CH3CONH(CH2)2NH
O
O O
OHHO
C
OH
(CH3)3COCONH(CH2)2NH
O
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Figure 6.  Potential points of interaction between UDP-Glc and the P2Y14-R.  Diagram of 
putative binding site for UDP-Glc depicting amino acid side chains that may form bonds with 
various atoms on the UDP-Glc molecule.  Tyr29 and Val32 lie in the amino terminal end; Asn104 
is in TM3; Arg253 is in TM6; Thr280, Ser284, Asn287, and Val288 are in TM7; Glu166, Lys171 
and Glu174 are in EL2; Lys277 is in EL3. 
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References 
 
Figure 7.  UDP-Glc analogues with 4’- and 2’-uracil ring modifications are novel 
agonists at the P2Y14-R.  COS-7 cells expressing P2Y14-R and Gq/i were radiolabeled with 
[3H]inositol, and incubated with varying concentrations of indicated compound for 45 min.  
A, 4-thio-UDP-Glc is equipotent to UDP-Glc.  B, 2-thio-UDP-Glc is >6X more potent than 
UDP-Glc at the P2Y14-R. 
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Chapter III.  UDP is a competitive antagonist at the 
human P2Y14 receptor 
Abstract 
G-protein coupled P2Y receptors (P2Y-R) are activated by adenine and uridine 
nucleotides.  The P2Y14 receptor (P2Y14-R) is activated by at least four naturally occurring 
UDP-sugars, with UDP-glucose (UDP-Glc) being the most potent agonist.  With the goal of 
identifying a competitive antagonist for the P2Y14-R, UDP was examined for antagonist 
activity in COS-7 cells transiently expressing the human P2Y14-R and a chimeric G protein 
that couples Gi-coupled receptors to stimulation of phosphoinositide hydrolysis.  UDP 
antagonized the agonist action of UDP-Glc, and Schild analysis confirmed the antagonism 
was competitive (pKB= 7.28).  UDPβS also antagonized the hP2Y14-R with an apparent 
affinity similar to that of UDP.  In contrast, no antagonist activity was observed with ADP, 
CDP, or GDP, and other uracil analogues also failed to exhibit antagonist activity.  
Antagonist activity of UDP was not observed at other human P2Y receptors.  In contrast to 
its antagonist action at the human P2Y14-R, UDP was a potent agonist (EC50 = 0.35 µM) at 
the rat P2Y14-R.  These results identify the first competitive antagonist of the P2Y14-R and 
demonstrate pharmacological differences between receptor orthologs. 
Introduction 
P2Y receptors are members of the superfamily of G-protein coupled receptors and are 
activated by adenine and uridine nucleotides and nucleotide-sugars.  At least eight receptors 
comprise the P2Y-R family.  P2Y1, P2Y2, P2Y4, and P2Y6 receptors are coupled to Gq and 
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activate phospholipase C, while P2Y12, P2Y13, and P2Y14 receptors couple to Gi, leading to 
the inhibition of adenylyl cyclase and activation of ion channels (Burnstock, 2006).  The 
P2Y11-R uniquely couples both to Gq to activate phospholipase C and to Gs to stimulate 
adenylyl cyclase (Communi et al., 1997; Qi et al., 2001). 
The human P2Y14-R was identified as the eighth legitimate member of the P2Y 
receptor family (Chambers et al., 2000).  UDP-glucose (UDP-Glc) was proposed to be the 
endogenous agonist for the P2Y14-R, with UDP-galactose, UDP-glucuronic acid, and UDP-
N-acetylglucosamine acting as less potent P2Y14-R agonists.  P2Y14-R mRNA was detected 
in a broad range of human tissues including placenta, stomach, intestine, adipose, brain, lung, 
spleen and heart, and also in specialized cells such as circulating neutrophils (Chambers et 
al., 2000; Scrivens and Dickenson, 2006).  The rat and mouse P2Y14-R exhibit 80% and 83% 
amino acid identity to the human receptor, and both rodent orthologs are activated by known 
agonists with a similar profile to that of the human P2Y14-R (Freeman et al., 2001).     
Cellular UDP-Glc is released in a constitutive manner into the medium of a broad 
range of cell types.  While most extracellular nucleotides are metabolized quickly, UDP-Glc 
accumulates in the medium of several cell lines (Lazarowski et al., 2003).  The mechanisms 
of UDP-Glc release and extracellular metabolism remain unclear.  Observations of UDP-Glc-
promoted signaling were reported in multiple types of immune cells (Fumagalli et al., 2003; 
Skelton et al., 2003; Scrivens and Dickenson, 2005; Muller et al., 2005), suggesting that the 
P2Y14-R may have a yet to be defined role in the regulation of immune system homeostasis.       
Characterization of the P2Y14-R has been slowed by the lack of a selective 
competitive antagonist.  We have identified and developed novel, selective ligands for 
several P2Y receptors that have proven useful for pharmacological resolution of molecularly 
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defined P2Y-R in cells and tissues (Boyer et al., 1996; Jacobson et al., 2006; Houston et al., 
2006; Houston et al., 2007).  Accordingly, we are interested in identifying a selective 
antagonist for the P2Y14-R.   
Ault and Broach (2006) recently used a yeast model system in which various 
nucleotides and nucleotide-sugars were examined for their ability to stimulate growth of 
mutant P2Y14-R-expressing yeast cells in studies focused on identification of mutant P2Y14 
receptors with differential agonist sensitivities.  Studies performed using one of these mutant 
receptors revealed that UDP antagonized UDP-Glc-promoted receptor activation in a 
concentration-dependent manner (Ault and Broach, 2006).  We hypothesized that UDP acts 
as a competitive antagonist at the wild-type P2Y14-R, and therefore, used a transfected COS-
7 cell system to investigate UDP activity at the human and rat P2Y14-R.  Here we show that 
UDP is a selective and competitive antagonist of the human P2Y14-R.  Thus, signals 
emanating from extracellular UDP apparently occur as a consequence of activation of the 
P2Y6-R as well as through antagonism of the P2Y14-R.  Surprisingly, UDP is a potent full 
agonist at the rat P2Y14-R. 
Methods 
Materials  
UDP-Glc, UDP, ADP, CDP, GDP, and 2-methyl-thio-ADP were purchased from 
SigmaAldrich (St. Louis, MO).  UP3U was synthesized according to Methods detailed in 
Pendergast et al (2001).  The source of UP4U was as previously reported (Ivanov et al 2007).  
ATP and UTP were purchased from GE Healthcare (Piscataway, NJ).  [32P]PPi was 
synthesized as described previously (Lazarowski et al., 2003).  UDPβS as well as a 
 74
mammalian expression vector for ENPP1 were generous gifts from Dr. José Boyer of Inspire 
Pharmaceuticals, Durham, NC. 
Cell Culture and Transfection 
COS-7 cells were grown on 12-well culture dishes and maintained in DMEM supplemented 
with 10% FBS and 4 mM L-glutamine at 37°C in a 10% CO2 environment.  Cells were 
transfected 48 h prior to assay with pcDNA3.1 expression vectors encoding either the human 
or rat P2Y14 receptor with an N-terminal Hemaglutinin epitope.  The expression vector for 
the hP2Y14-R was obtained as previously reported (Lazarowski et al 2003).  Transfections 
also included pcDNA3.1-Gαq/i, a vector that directs expression of a chimera of Gαq 
containing the last five amino acids of Gαi.  This chimeric G protein promotes activation of 
phospholipase C through Gαi-coupled receptors (Coward et al., 1999).  The levels of basal 
inositol phosphates increased markedly in COS-7 cells upon expression of human or rat 
P2Y14-R and Gαq/i.  Since we previously illustrated that UDP-sugars are basally released by 
various cell types (Lazarowski et al., 2003), in some experiments pcDNA3.1 expressing 
ENPP1 was co-transfected with the goal of hydrolyzing extracellular nucleotide sugars and 
potentially decreasing inositol phosphate accumulation in the absence of added P2Y14-R 
agonists.  FuGENE 6 (Roche Applied Science, Indianapolis, IN) was used as the transfection 
reagent following the manufacturer’s protocol. 
Inositol Phosphate Accumulation Assay 
Cells were labeled 8-18 h prior to assay with 0.5-3 µCi/ well [3H]-myo-inositol (American 
Radiolabeled Chemicals, St. Louis, MO) in inositol-free and serum-free DMEM.  Assays 
were initiated with the addition of 10 mM LiCl with or without drugs, and incubations 
continued for 45 min at 37°C.  Reactions were stopped by aspiration of medium and addition 
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of ice-cold 50 mM formic acid.  After neutralization with 150 mM ammonium hydroxide, 
[3H]inositol phosphates were isolated by Dowex column chromatography as described 
previously (Nakahata and Harden, 1987).  Stable cell lines for P2Y1, P2Y2, P2Y4, P2Y6, or 
P2Y11 receptors were generated in 1321N1 human astrocytoma cells as previously described 
(Nicholas et al., 1996; Kennedy et al., 2000).  Experiments testing the potential activity of 
UDP at the P2Y2-R and P2Y4-R included hexokinase to eliminate contaminating UTP as 
described previously in Nicholas et al. (1996).  Briefly, UDP was treated with 10 U/mL 
hexokinase in the presence of 22 mM glucose for 1 h at 37ºC, and 1 U/mL hexokinase was 
included in the assay buffer for the duration of the incubation.  Variability in cpm of 
[3H]inositol phosphate accumulation across experiments occurred due to differences in the 
amount of [3H]inositol utilized for labeling and/or the duration of the prelabeling period.   
Measurement of UDP-Glc in the cell medium 
Quantification of UDP-Glc was performed as previously described (Lazarowski et al. 2003).  
Briefly, incubations were in a final volume of 150 µl containing known or unknown amounts 
of UDP-glucose, 25 mM HEPES, pH 7.4, and 0.5 U/ml UDP-glucose pyrophosphorylase 
from baker's yeast (Sigma), and 100 nM [32P]PPi (200,000 cpm). Incubations were 
terminated by addition of 0.3 mM PPi and immediate heating of samples for 2 min at 95°C, 
and formation of [32P]UTP was quantified by high performance liquid chromatography as 
described (Lazarowski et al. 2003).   
Quantification of P2Y14-R expression 
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Cells were seeded in 12-well plates at 5 x 104 cells/well 3 days prior to assay and transfected 
with mammalian expression vectors as described above.  Cells were fixed with 0.4 ml of 4% 
paraformaldehyde for 30 min at room temperature, washed twice with 1 ml of HBSS plus 
Ca2+/Mg2+, and incubated for 30 min at room temperature with 0.4 ml of DMEM plus 50 mM 
HEPES, pH 7.1, and 10% fetal bovine serum. Cells were incubated with mouse HA.11 
monoclonal antibody at a 1:1000 dilution in 0.4 ml of medium for 1 h at room temperature. 
Following two washes with 1 ml of HBSS plus Ca2+/Mg2+, cells were incubated with 
[125I]rabbit anti-mouse IgG antibody diluted to 1:500 in 0.4 ml of medium for 2 h at room 
temperature. Following another series of washing steps, cells were solubilized in 0.4 ml of 1 
M NaOH overnight and transferred to glass tubes for quantification of radioactivity in a 
gamma counter.  
Rat P2Y14-R subcloning 
The rat homolog of the P2Y14-R (rP2Y14-R) was amplified from rat genomic DNA using Pfu 
polymerase with the following primers: (5’-
GAGACGCGTCCGACAACACAACAACCACAGAAC-3’) and (5’-
AGACTCGAGTTACAAAGTATCTGTGCTTTCC-3’).  The primers contained either a 
MluI (upstream primer) or a XhoI (downstream primer) restriction site, respectively (sites are 
underlined) to facilitate cloning.  The amplification conditions were 94°C for 5 min; 
35 cycles of 94°C for 45 s, 55°C for 45 s, 72°C for 90 s; and a final extension for 4 min at 
72°C.  The amplified rP2Y14-R fragment was digested with MluI and XhoI, purified, and 
ligated into a similarly digested, modified pcDNA3 expression vector, which fuses an HA-
epitope to Asp-2 at the N-terminus of the receptor.  An individual clone encoding the 
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receptor was sequenced and found to be identical to the published sequence (Freeman et al., 
2001).   
Data Analyses 
The results from each experiment are expressed as mean ± S.E. from triplicate samples, and 
were analyzed using GraphPad Prism 4.0 software. All experiments were repeated at least 
three times with similar results.  Schild analysis was performed using EC50 values from the 
concentration effect curves for UDP-Glc generated in the absence and presence of increasing 
concentrations of UDP.  The pKB was calculated using the equation: log ([A’]/[A] – 1) = log 
[B] – log pKB (Arunlakshana and Schild, 1959), where [A’] is the concentration of UDP-Glc 
necessary to produce fifty percent of the maximal effect in the presence of antagonist [B] and 
[A] is the concentration of agonist necessary to produce fifty percent of the maximal effect in 
the absence of antagonist.  Drug response data presented in Figs 3A, 5A-D, and 7B are 
normalized as a percentage of the response observed with a maximally effective 
concentration (usually 10 uM) of UDP-Glc.  Statistics were carried out using Student’s t test.  
Results 
Agonist activity of UDP-Glc at the hP2Y14-R. 
To assay the functional activity of the hP2Y14-R, we utilized COS-7 cells transiently 
co-expressing the hP2Y14-R and a Gαq/i chimera.  The Gαq/i chimera is a Gαq protein in 
which the last five amino acids at the carboxyl terminus have been substituted with those of 
Gαi.  This chimeric Gα subunit is activated by GPCRs that couple to the Gαi family of G-
proteins and signal through downstream Gαq effectors such as phospholipase C (Coward et 
al., 1999).  Expression of the hP2Y14-R or the Gαq/i chimera alone in COS-7 cells resulted in 
levels of [3H]inositol phosphate accumulation similar to that observed in cells expressing 
 78
empty vector alone.  [3H]Inositol phosphate accumulation was not changed by the addition of 
100 µM UDP-Glc to cells expressing empty vector, the hP2Y14-R, or Gαq/i (Fig. 1).  Co-
expression of the hP2Y14-R and Gαq/i resulted in increased [3H]inositol phosphate 
accumulation in the presence of buffer alone as we previously reported (Lazarowski et al., 
2003).  Addition of 100 µM UDP-Glc to cells co-expressing the hP2Y14-R and Gαq/i resulted 
in a two-fold increase in inositol phosphate accumulation, consistent with agonist-promoted 
activation of phospholipase C (Fig. 8). 
To investigate the nature of the hP2Y14-R-dependent [3H]inositol phosphate 
accumulation in the absence of added agonist, we co-expressed ENPP1 with the hP2Y14-R 
and Gαq/i in COS-7 cells with the goal of removing any released nucleotide/nucleotide-sugar 
potentially present in the medium.  UDP-Glc levels (3.6 ± 1.9 nM) in the bulk medium from 
COS-7 cells expressing hP2Y14-R and Gαq/i were similar to that of control cells (3.3 ± 0.3 
nM).  In contrast, co-expression of ENPP1 in cells also expressing hP2Y14-R and Gαq/i 
resulted in an approximately 78 % reduction in UDP-Glc levels (0.8 ± 0.5 nM) compared to 
control.  Although expression of ENPP1 alone had no effect on basal [3H]inositol phosphate 
accumulation, expression of ENPP1 with hP2Y14-R and Gαq/i resulted in an approximately 
40% decrease (p < 0.01) in basal [3H]inositol phosphate levels compared to cells expressing 
receptor and G protein alone (Fig. 9A).  Expression of ENPP1 had no effect on surface 
expression of the hP2Y14-R as quantified with an immunoassay (data not shown; see 
Methods), and did not notably change the concentration effect curve for added UDP-Glc 
(Fig. 9B).  Thus, we conclude that the hP2Y14-R-dependent elevation of [3H]inositol 
phosphate levels in the absence of added agonist occurs largely because of 
autocrine/paracrine release of P2Y14-R agonist.  However, these results do not entirely rule 
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out the possibility that the overexpressed P2Y14-R exhibits constitutive activity in this test 
system.     
Antagonist Effect of UDP at the hP2Y14-R. 
Four UDP-sugars were identified as agonists at the hP2Y14-R, and neither UTP nor 
UDP exhibited agonist activity (Chambers et al., 2000).  To determine whether UDP is an 
antagonist at the wild-type hP2Y14-R, we generated a series of concentration-effect curves 
for UDP-Glc-promoted stimulation of phospholipase C in the presence of increasing 
concentrations of UDP (Fig. 10A).  UDP caused a parallel rightward shift of the UDP-Glc 
concentration-effect curve, and Schild analysis (Fig. 10B) confirmed that the antagonism 
produced by UDP was competitive (slope = 1.15 ± 0.06, n = 3).  The pKB of UDP for 
antagonism of the hP2Y14-R was 7.28 ± 0.04.   
We also assessed whether UDP exhibited antagonist activity at other P2Y-R stably 
expressed in 1321N1 human astrocytoma cells.  P2Y1-R was maximally activated by 1 µM 
2MeSADP (Fig. 11A), P2Y2-R and P2Y4-R were each activated by 3 µM UTP (Fig. 11B, C), 
and P2Y11-R was activated by 100 µM ATP (Fig. 11D).  Although 10 µM UDP completely 
blocked a near-maximal concentration of UDP-Glc at the hP2Y14-R (Fig. 10), UDP had no 
effect at any other P2Y receptors tested.  Thus, we conclude that UDP is a selective 
antagonist at the hP2Y14-R.   
To determine whether the antagonist effect of UDP at the hP2Y14-R is specific to the 
uracil structure, we also tested other nucleotides and nucleotide derivatives as antagonists at 
the hP2Y14-R.  In contrast to the action of UDP, other nucleoside diphosphates including 
ADP, CDP, and GDP, at concentrations of 10 µM or 100 µM did not inhibit UDP-Glc (3 
µM)-promoted [3H]inositol phosphate formation (Fig. 12).  We also tested whether other 
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uridine-based molecules would antagonize activation of the hP2Y14-R by UDP-Glc.  Neither 
UTP, UP3U, nor UP4U inhibited UDP-Glc activation of the receptor, although each of these 
nucleotides, when tested alone, produced a stimulatory effect in untransfected COS-7 cells 
(data not shown).  The discovery of antagonist activity of UDP at the hP2Y14-R was also 
supported by the observation that the UDP analogue, UDPβS, inhibited activation of this 
receptor by UDP-Glc (Fig. 13).  The IC50 value observed for UDPβS was similar to that 
determined for UDP under the same assay conditions.  From these results, we conclude that 
UDP appears to be unique among naturally-occurring nucleotides in its capacity to inhibit 
UDP-Glc-dependent activation of the hP2Y14-R.       
Effects of UDP at the rP2Y14-R. 
Since pharmacological studies often are carried out with rat or mouse tissues, it is 
important to assess whether receptor orthologs exhibit pharmacological selectivity similar to 
those of human P2Y-R.  Based on the precedent that ATP acts as an antagonist at the human 
P2Y4-R but is an agonist at the rat P2Y4-R (Bogdanov et al. 1998; Kennedy et al. 2000), we 
compared the action of UDP at the rP2Y14-R with its action at the hP2Y14-R.  The rat P2Y14-
R, which exhibits approximately 80% amino acid sequence identity to the hP2Y14-R, and 
almost 90% identity in the transmembrane regions alone, was reported to display a similar 
UDP-sugar selectivity to that of the hP2Y14-R (Freeman et al., 2001), but the actions of other 
uridine nucleotides on the rP2Y14-R have not been reported.   
Expression of either the rP2Y14-R or Gαq/i in COS-7 cells had no effect on 
[3H]inositol phosphate accumulation as compared to untransfected cells, but co-expression of 
receptor and Gαq/i resulted in markedly increased basal accumulation (Fig. 14A).  Consistent 
with other reports (Freeman et al., 2001), UDP-Glc was a potent agonist at the rP2Y14-R 
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(Fig. 14B).  Whereas UDP had no effect on inositol phosphate accumulation in wild-type 
COS-7 cells, in cells expressing Gαq/i alone, or in cells expressing the rP2Y14-R alone (data 
not shown), concentration of UDP-dependent increases in formation of [3H]inositol 
phosphates occurred in COS-7 cells co-expressing the rat P2Y14-R with Gαq/i (Fig 14B).  The 
maximal stimulatory effect observed with UDP was similar to that observed with UDP-Glc 
as were the EC50 values of UDP (0.35 µM ± 0.17) and UDP-Glc (EC50 = 0.28 µM ± 0.05).  
No additivity was observed between UDP and UDP-Glc on rP2Y14-R-promoted [3H]inositol 
phosphate formation (Fig. 14C).   
Discussion 
In this study, we show that UDP is a competitive antagonist at the human P2Y14-R, 
and this action is receptor-selective since UDP does not inhibit agonist-promoted activation 
of other hP2Y receptors.  Moreover, the activity of UDP at the P2Y14-R is species-dependent 
since we observed that UDP is a potent, and apparently full, agonist at the rat P2Y14-R. 
Chambers et al. (2000) reported in their initial study of the hP2Y14-R that UDP has no 
agonist activity, and we observed similar results in the studies reported here.  Using a 
reporter system in yeast, Ault and Broach (2006) generated a mutant hP2Y14-R displaying a 
mutation in intracellular loop 1 and various mutations in several of the transmembrane 
regions.  This mutant, selected for its ability to support growth of yeast at lower 
concentrations of UDP-Glc than the wild-type receptor, exhibited an enhanced UDP-Glc-
stimulated response that was inhibited by UDP, and a KB in the micromolar range was 
reported.  The >20-fold higher potency of UDP observed in our studies likely reflects large 
differences in the assay systems employed.  For example, whereas incubations with 
nucleotide were for minutes in the current study they were for hours in assays measuring 
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P2Y14-R mediated regulation of growth of yeast.  Our results illustrate that UDP is a potent 
competitive antagonist of the wild-type hP2Y14-R.    
Demonstration of antagonist action at the hP2Y14-R suggests that UDP may have 
broader physiological importance as an extracellular signaling molecule than has been 
previously appreciated.  Both UDP and UDP-glucose are known to be released from cells, 
although the mechanisms of their release remain unclear.  UDP is the most potent and 
selective agonist of the hP2Y6-R (Lazarowski and Harden, 1994; Communi et al., 1996), and 
physiological responses attributed to UDP-initiated P2Y6-R-promoted signaling include 
modulation of IL-8 production in monocytes (Warny et al., 2001) and human mature 
dendritic cells (Idzko et al., 2004).  Additionally, UDP was observed to induce a positive 
inotropic effect in mouse cardiomyocytes (Wihlborg et al. 2006) and to promote ion transport 
in human placental cytotrophoblast cells (Roberts et al., 2006).  Our data indicate that 
potential contributions of the P2Y14-R to responses associated with UDP must be considered.  
While reported distribution of P2Y6-R mRNA overlaps with that of P2Y14-R mRNA in many 
cells and tissues, such as lung, heart, placenta, and neutrophils (Communi et al., 1996; Moore 
et al., 2001), it remains unclear whether the two receptor types are co-expressed in the same 
cells or in different cells that share the same extracellular space.     
The actions of extracellular neurotransmitters and hormones are highly regulated by 
their release, metabolism, and reuptake.  The possibility that direct antagonism of GPCR 
activation occurs by extracellular signaling molecules has been suggested by observations 
that ATP is a competitive antagonist of the hP2Y12-R (Cusack and Hourani, 1982; Bodor et 
al., 2003) and of the hP2Y4-R (Bogdanov et al., 1998; Kennedy et al., 2000).  The 
physiological relevance of UDP antagonism at the hP2Y14-R will be important to investigate, 
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as will the idea that UDP simultaneously activates the hP2Y6-R while inhibiting the hP2Y14-
R. 
Our finding that UDP has agonist activity at the rP2Y14-R was surprising.  Study of 
the rat and human receptors under identical conditions rules out trivial explanations of this 
observation.  These data do not unambiguously rule out the possibility that UDP is a partial 
agonist at the human receptor under some conditions.  However, the agonist versus 
antagonist action of the nucleotide at the rat versus human P2Y14-R has been observed over a 
broad range of expression levels of these two receptors.  Our activity data suggest that the 
binding affinity of UDP for the human and rat receptors in fact are quite similar, but 
development of a radioligand binding assay will be necessary to fully assess this assertion. 
The fact that the maximal agonist activity of UDP was similar to that of UDP-Glc over a 
broad range of P2Y14-R expression levels (data not shown) suggests that the intrinsic efficacy 
of UDP at the rat P2Y14-R is similar to that of UDP-Glc.      
The differential activity of UDP observed between the rat and human orthologs of the 
P2Y14-R shares similarities to the actions of ATP at the P2Y4-R.  Kennedy et al. (2000) 
compared the ligand selectivities of the rat and human P2Y4 receptors under conditions that 
minimize effects of released nucleotides and of extracellular bioconversion of nucleotides 
and observed that ATP is an agonist at the rat P2Y4-R and a competitive antagonist at the 
human P2Y4-R.  Residues in the second extracellular loop of the P2Y4 receptor are the 
primary determinants for the agonist versus antagonist activity of ATP between the two 
species orthologs (Herold et al., 2004).  Like the P2Y4-R, the P2Y14-R shares approximately 
80% amino acid sequence identity between the rat and human orthologs, with 90% identity 
when analysis is restricted to transmembrane regions only.  Recent work by Ko et al. (2007) 
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defines the human P2Y14 receptor through structure-activity studies in conjunction with 
molecular modeling studies.  Residues in the second extracellular loop of the hP2Y14-R are 
predicted to interact with the diphosphate moiety and hydroxyl groups on the hexose ring of 
UDP-Glc.  Comparative modeling of the rat P2Y14-R and receptor mutagenesis directed from 
these predictions may identify key domains responsible for agonist efficacy at the hP2Y14-R. 
The mouse P2Y14-R has been cloned and is reported to be activated by the same 
UDP-sugar agonists as the human and rat receptors (Freeman et al., 2001).  The rat and 
mouse P2Y14-R share 89% overall amino acid sequence identity and are essentially identical 
in their transmembrane spanning domains and the second extracellular loop.  Thus, we 
anticipate that the agonist action of UDP observed with the rat receptor will be similarly 
observed at the mouse P2Y14-R. 
The finding that UDP acts as a competitive antagonist at the hP2Y14-R provides an 
excellent template for rational synthesis of antagonist analogues that exhibit high affinity at 
the hP2Y14-R.  Our structure-activity studies of UDP analogues at the hP2Y6-R (Besada et 
al., 2006) also provide potential avenues for development of P2Y14-R antagonists that do not 
act as ligands for the P2Y6-R.  Synthesis of a hydrolysis-resistant competitive antagonist for 
the P2Y14-R is an obvious goal, as is a high affinity radiolabeled antagonist. 
UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine 
previously were identified as full or partial agonists at human and rodent P2Y14-R (Chambers 
et al., 2000; Freeman et al., 2001).  The pharmacological selectivity for the P2Y14-R is now 
broadened with the finding that UDP also acts at this receptor.    The identification of UDP as 
a competitive antagonist for the hP2Y14-R provides new insight into the physiological 
 85
regulation of this receptor, and should be of pharmacological importance in delineating the 
functional roles subserved by this signaling protein. 
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Figure 8.  hP2Y14-R- and Gαq/i-dependent increases in [3H]inositol phosphate 
accumulation.  COS-7 cells were transfected with empty vector or expression vectors for 
hP2Y14-R and/or Gαq/i as described in Methods.  Cells were labeled with [3H]inositol for 18 h 
prior to assay.  LiCl (10 mM) buffer was added to the cells to inhibit inositol 
monophosphatase, and the cells were simultaneously incubated in the absence or presence of 
10 µM UDP-Glc for 45 min.  [3H]Inositol phosphates were isolated as described in Methods.  
Data shown are means ± S.E. calculated from triplicate samples and are representative of 
results obtained in three independent experiments. 
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Figure 9.  Co-expression of ENPP1 reduces the basal activation of the hP2Y14-R.  COS-7 
cells were co-transfected with expression vectors for hP2Y14-R and Gαq/i with (+) or without 
(-) an expression vector for ENPP1.  A) [3H]Inositol-labeled cells were incubated with 10 
mM LiCl in the absence or presence of UDP-Glc.  * p<0.01  B) [3H]Inositol-labeled cells 
were incubated with 10 mM LiCl in the absence or presence of UDP-Glc at the indicated 
concentrations.  Data shown are means ± S.E. calculated from triplicate determinations. 
 
 
 
 
 88
 
 
Figure 10.  UDP is a competitive antagonist at the hP2Y14-R.  A)  [3H]Inositol-labeled 
COS-7 cells co-expressing hP2Y14-R and Gαq/i were incubated with LiCl (10 mM) and 
increasing concentrations of UDP-glucose in the absence or presence of the indicated 
concentrations of UDP:  ■, Buffer; ▲, 0.1 µM; ▼, 0.3 µM; ♦, 1 µM; ●, 3 µM; □, 30 µM;   , 
100 µM.  Data shown are means ± S.E. calculated from triplicate samples and are 
representative of results obtained in three independent experiments.  B)  EC50 values from 
the concentration-effect curves in (A) were used for Schild regression analysis.  The data 
shown are results from a representative experiment repeated three times to yield a mean pKB 
of 7.28 ± 0.04 and a slope of 1.15 ± 0.06. 
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Figure 11.  UDP is a selective antagonist at the hP2Y14-R.  [3H]Inositol-labeled 1321N1 
human astrocytoma cells stably expressing either the A) human P2Y1-R, B) human P2Y2-R, 
C) human P2Y4-R, or D) human P2Y11-R were incubated for 30 min with 10 mM LiCl with 
the cognate agonist (indicated), or 10 µM UDP, or both agonist and UDP, and inositol 
phosphate accumulation was quantified as described in Methods.  Data shown are means ± 
S.E. calculated from triplicate samples and are representative results obtained in three or 
more independent experiments.   
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Figure 12.  UDP is unique among nucleotide diphosphates for its antagonist effect at the 
hP2Y14-R.  A) CDP, B) ADP, C) GDP, or D) UDP (10 µM or 100 µM) and LiCl (10 mM) 
were applied simultaneously with 3 µM UDP-Glc to [3H]inositol-labeled COS-7 cells 
transiently expressing hP2Y14-R and Gαq/i.  Data were normalized to values from maximal 
activation of hP2Y14-R by UDP-Glc alone, and the LiCl alone value was subtracted from 
each data point.  The data shown in (A), (C), and (D) are results from a representative 
experiment repeated three times.  The data shown in (B) is the average of results from four 
experiments. 
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Figure 13.  Antagonist effect of UDPβS at the hP2Y14-R.  [3H]inositol-labeled COS-7 cells 
transiently expressing hP2Y14-R and Gαq/i were incubated with 10 mM LiCl in the absence 
(○) or presence (●) of 1 µM UDP-Glc in the presence of the indicated concentrations of 
UDPβS for 30 min.  The data shown are means ± S.E. of triplicate determinations, and the 
results are representative of those obtained in three experiments. 
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Figure 14.  Agonist effect of UDP-Glc and UDP at the rP2Y14-R.  A) COS-7 cells 
transfected with an expression vector for Gαq/i and with empty vector and/ or rP2Y14-R were 
[3H]inositol-labeled and incubated with 10 mM LiCl in the absence or presence of 10 µM 
UDP-Glc.  B) [3H]Inositol-labeled COS-7 cells transiently expressing the rP2Y14-R and Gαq/i 
were incubated with 10 mM LiCl and UDP-Glc or UDP at the indicated concentrations, and 
[3H]inositol phosphate accumulation was quantified as described in Methods.  Data shown 
are means ± S.E. calculated from triplicate samples and are results from a representative 
experiment repeated three times, yielding an EC50 of 0.28 µM ± 0.05 for UDP-Glc, and 0.35 
µM ± 0.17 for UDP.  Data were normalized to the maximal activation of rP2Y14-R by UDP-
Glc.  C) Cells incubated with UDP-Glc (10 µM) + UDP (100 µM) exhibited no difference in 
[3H]inositol phosphate accumulation compared to accumulation in the presence of either 
agonist alone.  Data shown are means ± S.E. calculated from triplicate samples and are 
representative of results obtained in three independent experiments. 
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Chapter IV.  Gi-dependent cell signaling responses of the 
human P2Y14-receptor in model cell systems 
Abstract 
 Eight G protein-coupled receptors comprise the P2Y receptor family of cell signaling 
proteins.  The goal of the current study was to define native cell signaling pathways regulated 
by the uridine nucleotide sugar-activated P2Y14 receptor (P2Y14-R).  The P2Y14-R was stably 
expressed in HEK293 and C6 rat glioma cells by retroviral infection.  Nucleotide sugar-
dependent P2Y14-R activation was examined by measuring inhibition of forskolin-stimulated 
cyclic AMP accumulation.  The effect of P2Y14-R activation on mitogen activated protein 
kinase (MAPK) signaling also was studied in P2Y14-R-HEK293 cells and in differentiated 
HL-60 human myeloid leukemia cells.  UDP-glucose, UDP-galactose, UDP-glucuronic acid 
and UDP-N-acetylglucosamine promoted inhibition of forskolin-stimulated cyclic AMP 
accumulation in P2Y14-R-HEK293 and P2Y14-R-C6 cells, and this signaling effect was 
abolished by pretreatment of cells with pertussis toxin.  Inhibition of cyclic AMP formation 
by nucleotide sugars also was observed in direct assays of adenylyl cyclase activity in 
membranes prepared from P2Y14-R-C6 cells.  UDP-glucose promoted concentration-
dependent and pertussis toxin-sensitive extracellular regulated kinase (ERK) 1/2 
phosphorylation in P2Y14-R-HEK293 cells.  P2Y14-R mRNA was not observed in wild type 
HL-60 cells, but was readily detected in DMSO-differentiated cells.  Consistent with this 
observation, no effect of UDP-glucose was observed in wild type HL-60 cells, but UDP-
glucose-promoted pertussis-sensitive activation of ERK1/2 occurred after differentiation.  
These results illustrate that the human P2Y14-R signals through Gi to inhibit adenylyl 
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cyclase, and P2Y14-R activation also leads to ERK1/2 activation.  This work also identifies 
two stable P2Y14-R-expressing cell lines and differentiated HL-60 cells as model systems for 
the study of P2Y14-R-dependent signal transduction. 
Introduction 
The P2Y14-R is a seven-transmembrane-spanning G-protein coupled receptor that is 
activated by UDP-glucose (UDP-Glc) and other UDP-sugars (Chambers et al., 2000).  
P2Y14-R mRNA is expressed in stomach, intestine, placental and adipose tissues, lung, heart, 
and throughout the brain, as well as in many types of immune cells (Lee et al., 2003; Moore 
et al., 2003; Skelton et al., 2003; Scrivens and Dickenson, 2006).  Consistent with its 
prominent immune cell expression, the P2Y14-R has been implicated in several immune cell 
functions.  Moore and colleagues (2003) reported that P2Y14-R mRNA is upregulated in 
several brain regions after immunological challenge of mice with lipopolysaccharide.  
Additionally, UDP-Glc was reported to promote chemotaxis of bone marrow-derived 
hematopoietic stem cells (Lee et al., 2003). 
The P2Y14-R is a member of a subgroup of P2Y receptors, which includes the P2Y12 
and P2Y13 receptors thought primarily to activate heterotrimeric G proteins of the Gi family, 
but a comprehensive understanding of the signal transduction pathways activated by the 
P2Y14-R is not available.  Nonetheless, several reports are consistent with the idea that the 
P2Y14-R couples to Gi.  For example, Chambers and his colleagues illustrated in their initial 
study of the cloned human P2Y14-R that UDP-glucose promotes pertussis toxin-sensitive 
binding of radiolabeled GTPγS to membranes prepared from HEK293 cells expressing this 
receptor.  Modest UDP-glucose-promoted inhibition of cyclic AMP accumulation also has 
been reported for murine T-lymphocytes (Scrivens and Dickenson, 2005), human neutrophils 
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(Scrivens and Dickenson, 2006), and C6 glioma cells (Krzeminski et al., 2008), although the 
effects were not shown unambiguously to involve the P2Y14-R.  Other pharmacological 
studies of the P2Y14-R have relied on coexpression with the promiscuous G protein, Gα16 
(Chambers et al., 2000), or with a chimeric Gq (Moore et al., 2003; Fricks et al., 2008) 
engineered to couple Gi-activating receptors to activation of phosphoinositide hydrolysis and 
Ca2+ mobilization (Coward et al., 1999). 
Studies of the P2Y14-R have been limited by inability to detect and quantify receptor 
expression directly through the use of antibodies or radioligand binding assays, and also by 
the absence of high affinity, non-hydrolyzable, selective agonists and competitive antagonists 
to verify receptor-specific signal transduction.  It is critical that we understand the cell 
signaling processes engaged in response to P2Y14-R activation, and with this goal in mind, 
we generated two different cell lines that stably express the human P2Y14-R.  Robust P2Y14-
R-dependent inhibition of adenylyl cyclase was observed in both cell lines, and P2Y14-R-
dependent MAP kinase signaling was studied in P2Y14-R-HEK293 cells.  We also discovered 
that expression of native P2Y14-R is induced during differentiation of HL-60 myeloid 
leukemia cells, and that UDP-glucose promotes activation of MAP kinase signaling in these 
cells.  The model cell systems reported here should provide useful platforms for investigation 
of the P2Y14-R at the cellular and biochemical level. 
Methods 
Cell Culture   
HEK293 cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 10% fetal bovine serum (FBS) at 37ºC in a 10% CO2 environment.  C6 rat glioma cells 
were cultured in DMEM supplemented with 5% FBS in a 5% CO2 environment.  HL-60 cells 
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were maintained in Iscove’s medium supplemented with 10% FBS.  Differentiation of HL-60 
cells was achieved by inclusion of 1.3% DMSO in the culture medium for 5 days (Servant et 
al., 2000).   
P2Y14-R Expression   
Human P2Y14-R cDNA was amplified and ligated into the retroviral expression vector 
pLXSN as described previously (Wolff et al., 2005).  Retrovirus encoding the P2Y14-R was 
produced in PA317 cells according to the method of Johnson and colleagues (Johnson et al., 
1998) and was used to infect HEK293 cells or C6 glioma cells.  Geneticin-resistant cells 
were selected for two weeks in medium containing 0.4 mg/ml G418.  Clonal HEK293 cells 
stably expressing the hP2Y14-R were obtained by performing serial dilutions of cells in 96-
well plates, and growing clonal populations from a single cell under selection medium.  
Membrane Preparation 
Membranes were prepared as described previously (Smith and Harden, 1985).  Briefly, 
P2Y14-R-C6 rat glioma cells were grown on 150 mm dishes until confluent.  Cells were 
washed gently with PBS and then lysed with ice-cold 1 mM Tris, pH 7.4.  Cells were 
harvested by scraping dishes and homogenized with a glass homogenizer for ten strokes.  
Lysates were centrifuged at 40,000 x g for 10 min.  Membranes were resuspended in 10 mM 
Tris, pH 7.4, containing 1 mM EDTA and centrifuged again at 40,000 x g for 10 min.  
Washed membranes were resuspended in assay buffer (25 mM HEPES, pH 7.4, 5 mM MgCl, 
150 mM NaCl, 1 mM EDTA) and used immediately. 
Cyclic AMP Accumulation 
Cells were grown in 24-well plates and incubated with 1 µCi [3H]adenine/well in serum-free 
DMEM for 2 h prior to assay.  Assays were initiated by the addition of HEPES-buffered, 
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serum-free DMEM containing 500 µM 3-isobutyl-1-methyl-xanthine (IBMX), with or 
without drugs, and incubation continued for 12 min at 37ºC.  Incubations were terminated by 
aspiration of medium and addition of 450 µL ice-cold 5% trichloroacetic acid.  [3H]Cyclic 
AMP was isolated by sequential Dowex and alumina chromatography (Salomon et al., 1974) 
and quantified by liquid scintillation counting. 
Adenylyl Cyclase Activity 
Quantification of adenylyl cyclase activity was carried out according to the procedure 
described previously (Harden et al., 1982).  Briefly, assay tubes on ice contained drug or 
vehicle and a reaction mix of assay buffer containing, at final assay concentrations, 0.01 mM 
[α-32P]ATP (10-15 cpm/pmol), 0.5 mM [3H]cyclic AMP (10,000 cpm/assay), 8 mM creatine 
phosphate, creatine phosphokinase (6 U/assay), 0.01 mM GTP, 0.5 mM IBMX, 25 mM 
HEPES (pH 7.5), 5 mM MgSO4, 2 mM EDTA, and 150 mM NaCl.  Assays were initiated by 
the addition of 100 µg of membrane protein, and the incubations were carried out for 12 min 
at 30ºC.  The reaction was terminated with addition of 0.85 mL of ice-cold 5% trichloroacetic 
acid.  [32P]Cyclic AMP was isolated by sequential Dowex and alumina chromatography and 
quantified by liquid scintillation counting.  Recovery of [3H]cyclic AMP over columns 
averaged 50-60 %.     
 MAP Kinase Activation Assays 
HEK293 cells were grown on 12-well plates until 70-90% confluent.  Cells were serum-
starved 24 h prior to assay.  Drugs were added to cells for the indicated times, and the assay 
was terminated by aspiration of medium.  The cells were washed once with PBS, and 
Laemmli buffer containing 60 µM dithiothreitol (DTT) was added to each well.  The 
resultant cell lysates were passed through a 27G needle ten times, heated to 95ºC for five 
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min, and proteins resolved by electrophoresis on a 12.5% polyacrylamide gel.  Proteins were 
transferred to a nitrocellulose membrane, blocked with 5% BSA, washed with TBST (20 mM 
Tris, pH 7.4, 120 mM NaCl, 0.1% Tween20), and then incubated with antibody for phospho-
ERK1/2, phospho-p38, or phospho-JNK, according to the manufacturer’s directions.  After 
washing with TBST, membranes were incubated with horseradish peroxidase-conjugated 
goat-anti-mouse (phospho-ERK1/2, phospho-JNK) or goat-anti-rabbit (phospho-p38) 
antibody, membranes were washed, then incubated with chemiluminescent substrate (Pico 
West system, Thermo Fisher Scientific, Waltham, MA) and exposed to film.  Membranes 
were stripped with 200 mM glycine, pH 2.6, for 1 h at 25ºC, then re-probed with a primary 
antibody against total MAP kinase to verify equal loading of lanes.  HL-60 cells were serum-
starved 24 h prior to the assay, and resuspended in Hanks Buffered Salt Solution for the 
assay at a density of 5x106 cells/mL, 0.2 mL/assay.  Drugs were added for the indicated 
times, and the cells were lysed by adding one volume of Laemmli buffer containing 60 µM 
DTT to the cells.  Lysates were analyzed as described above.   
Data Analysis 
EC50 values were determined using Prism software (GraphPad, San Diego, CA) and are 
presented as mean ± SE.  Statistical significance was determined by Analysis of Variance 
(ANOVA), and p < 0.02 was considered statistically significant.  All experiments were 
repeated at least three times. 
Materials 
IBMX, creatine phosphate, creatine phosphokinase, forskolin, formyl-Met-Leu-Phe (fMLP), 
and GTP were purchased from SigmaAldrich (St. Louis, MO).  UDP-glucose, UDP-
galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine were all from FLUKA, 
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purchased through SigmaAldrich.  HPLC analysis of the UDP-Glc used in the current 
experiments revealed >98% purity.  ATP was purchased from GE Healthcare (Piscataway, 
NJ).  Pertussis toxin was purchased from List Biologicals (Campbell, CA).  [3H]Adenine and 
[3H]cyclic AMP were purchased from American Radiolabeled Chemicals (St. Louis, MO).  
[α-32P]ATP was purchased from PerkinElmer (Waltham, MA).  Antibodies for P-ERK1/2, 
ERK1/2, P-p38, p38, P-JNK, and JNK were purchased from Cell Signaling Technologies 
(Beverly, MA).  All cell culture medium and serum was from Gibco (Invitrogen, Carlsbad, 
CA).  PAR agonist peptide SLIGKV was a generous gift from Dr. Joann Trejo.  Anisomysin 
and sorbitol were kind gifts from Dr. Gary Johnson. 
Results 
UDP-sugars promote inhibition of forskolin-stimulated cyclic AMP formation in cells stably 
expressing the human P2Y14-R 
To examine potential regulation of adenylyl cyclase activity downstream of the 
human P2Y14-R, we stably expressed this receptor in HEK293 cells.  UDP-Glc promoted 
concentration-dependent inhibition of forskolin-stimulated accumulation of cyclic AMP in 
P2Y14-R-expressing HEK293 cells.  An EC50 value of 82 ± 11 nM (n = 3) was observed for 
UDP-Glc, and the maximal inhibition of forskolin-stimulated cyclic AMP accumulation 
ranged from 60-80% (Fig. 15).  In contrast, no effect of UDP-Glc was observed on basal or 
forskolin-stimulated cyclic AMP accumulation in HEK293 cells infected with vector alone.  
Pre-incubation of P2Y14-HEK293 cells with pertussis toxin resulted in complete loss of 
UDP-Glc-dependent inhibition of cyclic AMP accumulation, indicating that the P2Y14-R 
signals through Gα-subunits of the Gi family.   
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While UDP-Glc is reported to be a full agonist at the P2Y14-R, several studies of the 
P2Y14-R have reported variable effects of other nucleotide-sugars (Chambers et al., 2000; 
Scrivens and Dickenson, 2006).  Therefore, we tested the capacity of UDP-sugars to activate 
the P2Y14-R in P2Y14-HEK293 cells.  UDP-galactose, UDP-glucuronic acid, and UDP-N-
acetylglucosamine all promoted inhibition of cyclic AMP accumulation and the maximal 
inhibition observed was similar to that of UDP-Glc.  The potencies of UDP-galactose and 
UDP-glucuronic acid were similar to that of UDP-Glc, while UDP-N-acetylglucosamine 
exhibited an approximately 10-fold higher EC50 value (Fig. 16 and Table 4).   
We concluded it important to stably express the P2Y14-R in several cell backgrounds.  
Previous studies by our and other labs revealed robust inhibition of adenylyl cyclase in C6 rat 
glioma cells expressing several different G protein-coupled receptors (Schachter et al., 1997; 
Thomas et al., 2000; Castillo et al., 2007).  Therefore, we also infected C6 cells with 
recombinant pLXSN virus harboring the hP2Y14-R coding sequence.  Again, whereas UDP-
Glc had no effect on cyclic AMP accumulation in C6 cells expressing empty vector alone, 
robust inhibitory effects were observed with UDP-Glc in P2Y14-R-expressing C6 cells.  An 
EC50 value of 107 ± 68 nM was determined and up to 90% inhibition of forskolin-stimulated 
accumulation of cyclic AMP occurred in the presence of a maximally effective concentration 
of UDP-Glc.  The action of UDP-Glc in P2Y14-R-C6 cells was completely blocked by pre-
treatment of the cells with pertussis toxin (Fig. 17).  The concentration-dependent inhibition 
of cyclic AMP formation with other UDP-sugars also was established, and the EC50 values 
are reported in Table 4.   
Effects of UDP-sugars on adenylyl cyclase activity in membranes from P2Y14-R-expressing 
C6 cells 
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Based on the robust P2Y14-R-dependent inhibition of cyclic AMP accumulation 
observed in C6 glioma cells, we also isolated plasma membrane-enriched fractions to 
determine whether UDP-Glc- and P2Y14-R-dependent inhibition of adenylyl cyclase activity 
could be observed in a cell-free system.  While no effect of UDP-Glc was observed in 
membranes from control cells, approximately 50% inhibition of forskolin-stimulated 
adenylyl cyclase activity was observed in the presence of 10 μM UDP-Glc in membranes 
isolated from P2Y14-R-C6 glioma cells (Fig. 18).  This UDP-Glc-promoted response did not 
occur in membranes from P2Y14-R-C6 cells pretreated with pertussis toxin.           
MAP kinase activation by UDP-glucose in P2Y14-R-HEK293 cells 
Many important biological processes are regulated by MAP kinase signaling 
pathways.  To assess the capacity of the P2Y14-R to activate MAP kinase signaling cascades, 
P2Y14-R-HEK293 cells were treated with UDP-Glc and cell lysates were analyzed for 
phosphorylated ERK1/2 by Western blotting.  Whereas no effect was observed in mock-
infected cells, UDP-Glc-dependent ERK1/2 phosphorylation occurred in P2Y14-R-HEK293 
cells (Fig. 19A). 
The time course for UDP-Glc activation of ERK1/2 was compared to that occurring 
as a consequence of activation of the protease activated receptor-2 (PAR2), which is natively 
expressed in HEK293 cells (Amadesi et al., 2004; Dai et al., 2007).  Incubation of cells with 
the PAR2 agonist peptide SLIGKV (100 µM) resulted in marked phosphorylation of ERK1/2 
within 5 min, but phosphorylation quickly diminished thereafter.  In contrast, UDP-Glc-
dependent activation of ERK1/2 was not maximal until at least 15 min of incubation and was 
retained for at least 30 min.  The effects of UDP-Glc on ERK1/2 phosphorylation were 
concentration-dependent, and the EC50 (30 nM) observed was similar to that obtained in 
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studies of inhibition of cyclic AMP accumulation in these cells (Fig 19C).  As was observed 
in the studies of adenylyl cyclase activity, P2Y14-R-regulated ERK1/2 phosphorylation was 
not observed in cells preincubated with pertussis toxin (Fig. 19B).   
The capacity of the P2Y14-R to activate p38 and Jun-N terminal kinase (JNK) also 
was examined.  Although p38 was phosphorylated with a peak response observed within 5 
min after treatment of cells with sorbitol, no UDP-Glc-dependent activation of p38 was 
observed at any time point up to 60 min (Fig 19D).  In contrast to a robust activation 
observed in the presence of anisomycin, we also observed no effects of UDP-Glc on JNK 
phosphorylation (Fig. 19D). 
Functional P2Y14-R are endogenously expressed in differentiated HL-60 cells  
With the goal of identifying a cell line that natively expresses the P2Y14-R, we tested 
by RT-PCR several candidate cell lines previously reported to express P2Y14-R mRNA, as 
well as other cell lines derived from tissues reported to express this receptor (Chambers et 
al., 2000; Moore et al., 2003; Skelton et al., 2003).  Although no P2Y14-R mRNA was 
detected in undifferentiated HL-60 cells, differentiation of these cells with 1.3% DMSO to a 
neutrophil-like cell resulted in a marked increase in expression of P2Y14-R mRNA (data not 
shown). 
We also investigated the cell signaling responses discussed above to determine 
whether functional P2Y14-R could be observed in differentiated HL-60 cells.  In multiple 
experiments, 100 µM UDP-Glc exhibited no effect on cyclic AMP accumulation promoted 
by either forskolin, amthamine, an agonist for the Gs-coupled H2 histamine receptor, or 
forskolin + amthamine (data not shown).  Although a formyl peptide receptor (FPR) is 
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natively expressed by HL-60 cells (Boulay et al., 1990; Klinker et al., 1996), we also failed 
to observe effects of 1 µM fMLP on cyclic AMP accumulation in these cells. 
Potential activation of the MAP kinase signaling pathway also was studied in HL-60 
cells.  Whereas no effect of UDP-Glc was observed in wild type cells, time-dependent 
activation of ERK1/2 by UDP-Glc was observed after differentiation of the cells.  This effect 
was apparent within 5 min and peaked within 30 min (Fig. 20A).  In contrast to the time 
course of the phosphorylation response to UDP-Glc, cells treated with 1 µM fMLP exhibited 
a robust ERK1/2 activation at 5 min that quickly diminished thereafter (Fig. 20B).  Neither 
UDP-Glc- nor fMLP-dependent ERK1/2 activation was observed in cells pre-incubated with 
pertussis toxin (Fig 20C), consistent with the notion that the UDP-Glc-promoted ERK1/2 
activation in differentiated HL-60 cells occurs through a mechanism involving Gi in 
differentiated HL-60 cells. 
Discussion  
In this report, we demonstrate that the human P2Y14-R couples to inhibition of 
adenylyl cyclase in a pertussis toxin-sensitive manner in HEK293 and C6 cells stably 
expressing this receptor.  This work provides the first unequivocal demonstration of P2Y14-
R-dependent inhibition of adenylyl cyclase in a membrane preparation.  Robust stimulation 
of MAP kinase signaling also occurs with activation of the P2Y14-R.  This was the 
predominant activity observed with native P2Y14-R in differentiated HL-60 human myeloid 
leukemia cells. 
UDP-Glc is released from many cell types.  This phenomenon was initially 
demonstrated by Lazarowski and colleagues who illustrated both basal and mechanically-
induced release of UDP-Glc from multiple mammalian cell types (Lazarowski et al., 2003).  
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Constitutive release of UDP-Glc also occurs in yeast (Esther et al., 2008).  Although the 
mechanism(s) underlying UDP-Glc release is not well-established, calcium-dependent 
release of UDP-Glc was demonstrated in Calu-3 cells (Kreda et al., 2007), and UDP-Glc 
release occurred downstream of thrombin receptor-promoted signaling pathways in human 
astrocytoma 1321N1 cells (Kreda et al., 2008). 
UDP-sugars in addition to UDP-Glc are predictably present in the extracellular space.  
UDP-glucose, UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine all were 
previously reported as potent agonists of the P2Y14-R in test systems that involved 
coexpression of the receptor with a phospholipase C-activating G protein (Chambers et al., 
2000; Freeman et al., 2001). Our results measuring responses of a native signaling pathway 
also indicate that these four UDP-sugars are full agonists and exhibit relatively similar 
potencies.   It remains to be elucidated which one or more of these molecules is the 
endogenous agonist(s) for the receptor.  Indeed, it is likely that multiple UDP-sugars are 
physiological agonists for the P2Y14-R, such that the activating ligand may differ according 
to tissue or cell type. 
Our findings that neither UDP-Glc nor fMLP had an effect on stimulated cyclic AMP 
accumulation in differentiated HL-60 cells indicates that activated Gi does not couple to 
inhibition of adenylyl cyclase in these cells.  Perhaps the isoforms of adenylyl cyclase 
expressed in these cells are not subject to inhibition by Gi.  HL-60 cells gain a neutrophil 
phenotype upon differentiation, and therefore are likely to reflect receptor-promoted 
signaling responses that are characteristic of neutrophils.  Receptor-promoted inhibition of 
adenylyl cyclase has not been unequivocally demonstrated in neutrophils, and we are 
unaware of studies clearly defining the signaling pathways downstream of Gi-coupled 
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receptors in this tissue.  A small inhibition of cyclic AMP accumulation was reported to 
occur upon incubation of neutrophils with UDP-Glc (Scrivens and Dickenson, 2006).  
However, since none of the other P2Y14-R agonists inhibited forskolin-promoted cyclic AMP 
formation in neutrophils, it is unclear whether this effect was in fact dependent on either 
UDP-Glc or the P2Y14-R. 
Gi-coupled GPCR predictably activate MAP kinase signaling, and we illustrate here 
that UDP-Glc-dependent activation of ERK1/2 occurs in P2Y14-R-HEK293 cells.  Although 
P2Y14-R were not detected in undifferentiated HL-60 cells, message for the P2Y14-R was 
observed upon differentiation of HL-60 cells, and occurrence of UDP-Glc-promoted MAP 
kinase signaling indicated the presence of functional P2Y14-R.  HL-60 cells have been used 
as a model of neutrophil-like cells that undergo differentiation-associated morphological and 
functional changes including up-regulation of chemoattractant receptors and the capacity to 
chemotax (Hauert et al., 2002).  Differentiated HL-60 cells exhibit capacities to generate 
superoxide, ingest particles, and degranulate with efficiencies similar to that of neutrophils 
(Newburger et al., 1979).  In addition, they have distinct technical advantages over primary 
cells, such as viability and transfectability.  Differentiated HL-60 cells also have been used as 
a model system for studies of FPR, and consistent with previous observations (Rane et al., 
1997; Christophe et al., 2002; Paruch et al., 2006), we observed fMLP-promoted ERK1/2 
activation in differentiated HL-60 cells.  These findings establish differentiated HL-60 cells 
as a model system for investigation of biological functions of the P2Y14-R. 
The duration of P2Y14-R-promoted ERK1/2 phosphorylation in HEK293 cells and 
HL-60 cells was prolonged compared with that of other G protein coupled receptors.  PAR2, 
which promoted very transient ERK1/2 activation in HEK293 cells, is known to couple to Gi, 
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as well as to G12/13 and Gq (Fyfe et al., 2005).  The fMLP receptor, FPR, has been reported 
to couple to Gi, but the mechanism linking FPR to ERK1/2 phosphorylation is not clear 
(Selvatici et al., 2006; Huet et al., 2007; Kam et al., 2007).  Therefore, it is possible that the 
signaling pathway(s) responsible for P2Y14-R-promoted MAP kinase signaling differs from 
that engaged by PAR2 or FPR.  We speculate that pertussis toxin-sensitive Gα-subunits are 
necessary but not sufficient and additional pathways or regulatory mechanisms are involved 
in the MAP kinase response downstream of one or more of these receptors.  Observation of 
receptor-specific differences in the time course of stimulation of ERK1/2 phosphorylation 
has led to the suggestion that short term (e.g. 5 min) versus long-term receptor-dependent 
activation (e.g. 30-60 min) may promote distinct cellular functions.  For example, short-term 
ERK1/2 activation may be important for cell migration whereas sustained ERK1/2 activation 
may play a more critical role in cell proliferation (Luttrell, 2005; May and Hill, 2008).  Our 
studies do not rule out the possibility that the P2Y14-R desensitizes at a slower rate than 
PAR2 in HEK293 cells or FPR in HL-60 cells.  Additional studies will be necessary to 
address questions about the mechanism of P2Y14-R-dependent activation of MAP kinase, but 
its pertussis toxin sensitivity clearly indicates that Gi is an important signaling component in 
the pathway. 
In summary, this work unequivocally demonstrates that the human P2Y14-R promotes 
inhibition of adenylyl cyclase and activation of MAP kinase signaling pathways.  Our work 
also provides several model cell lines for study of P2Y14-R signaling as well as its potential 
role in neutrophil biology. 
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Table 4.  EC50 values for P2Y14-R agonists in P2Y14-HEK293 and P2Y14-C6 cells. 
[3H]Adenine-labeled cells were treated with IBMX (200 µM), forskolin (30 µM), and 
varying concentrations of either UDP-glucose, UDP-galactose, UDP-glucuronic acid, or 
UDP-N-acetylglucosamine for 15 min.  [3H]Cyclic AMP was quantified as described in 
Methods.  EC50 values were determined with GraphPad Prism software and are presented as 
mean ± SE of results from three experiments. 
 
Agonist 
P2Y14-HEK293 
EC50 ± SE, nM 
P2Y14-C6 
EC50 ± SE, nM 
UDP-glucose 82 ± 11 92 ± 51 
UDP-galactose 96 ± 29 240 ± 53 
UDP-glucuronic acid 60 ± 7 108 ± 66 
UDP-N-acetylglucosamine 919 ± 205 225 ± 68 
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Figure 15.  Concentration-dependent and pertussis toxin-sensitive inhibition of cyclic AMP 
accumulation promoted by UDP-Glc in P2Y14-HEK293 cells.  Empty vector-infected (left 
panel) or P2Y14-R-expressing (middle panel) cells were labeled with [3H]adenine 18 h prior to 
assay.  Cells were incubated with 200 µM IBMX  in the absence (□) or presence of 30 µM 
forskolin  and the indicated concentrations of UDP-Glc (■) for 12 min prior to quantification of 
[3H]cyclic AMP accumulation.  P2Y14-R-expressing (right panel) cells were preincubated with 
100 ng/mL pertussis toxin for 4 h,and [3H]cyclic AMP accumulation was measured in the 
presence of 200 µM IBMX alone (open bars), 200 µM IBMX + 30 µM forskolin (filled bars), or 
200 µM IBMX + 30 µM forskolin + 10 µM UDP-Glc (hatched bars). The data shown are 
presented as mean ± SE and are representative of results from three independent experiments. 
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Figure 16.  UDP-galactose, UDP-glucuronic acid, and UDP-N-acetylglucosamine inhibit 
accumulation of cyclic AMP in P2Y14-HEK293 cells.  [3H]Adenine-labeled P2Y14-HEK293 
cells were incubated with 200 µM IBMX alone (□) or IBMX with 30 µM forskolin and varying 
concentrations of UDP-glucose (■), UDP-galactose (♦), UDP-glucuronic acid (▲), or UDP-N-
acetylglucosamine (▼).  Data shown are mean ± SE and are representative of results of three 
independent experiments. 
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Figure 17.  UDP-Glc promotes pertussis toxin-sensitive inhibition of cyclic AMP 
accumulation in P2Y14-C6 cells.  Empty vector-infected (left panel) C6 rat glioma cells were 
prelabeled with [3H]adenine and then incubated in the presence of 200 µM IBMX alone (open 
bar), 200 µM IBMX + 30 µM forskolin (filled bar), or 200 µM IBMX + 30 µM forskolin +  
10 µM UDP-Glc (striped bar).  P2Y14-C6 cells (right panel) were incubated in the absence or 
presence of 100 ng/mL pertussis toxin prior to quantification of [3H]cyclic AMP 
accumulation in the presence of 200 µM IBMX alone (open bars), 200 µM IBMX + 30 µM 
forskolin (filled bars), or 200 µM IBMX + 30 µM forskolin +  10 µM UDP-Glc (striped bars).  
Data shown are presented as mean ± SE and are representative of results from three 
independent experiments. 
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Figure 18.  UDP-Glc-dependent inhibition of adenylyl cyclase by UDP-Glc in membranes 
from P2Y14-C6 cells.    Membranes were isolated from P2Y14-C6 cells or from cells pretreated 
with 100 ng/mL pertussis toxin overnight.  Membranes were incubated with 200 µM IBMX in 
the absence (open bars) or presence (filled bars) of 30 µM forskolin, or with 200 µM IBMX + 
30 µM forskolin + 10 µM UDP-Glc as described in Methods.  [32P]Cyclic AMP was isolated by 
sequential Dowex-alumina chromatography.  Data shown are the mean ± SE of three 
independent experiments, plotted as a percentage of maximal forskolin-stimulated enzyme 
activity.  
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Figure 19.  UDP-Glc-promoted activation of MAP kinase signaling in P2Y14-HEK293 
cells.  A)  Empty vector or P2Y14-R-expressing HEK293 cells were serum-starved for 18 h 
and then incubated with 100 µM UDP-Glc or 100 µM SLIGKV for the times indicated.  
Samples were probed for phospho-ERK1/2 and ERK1/2 as described in Methods.  B)  Cells 
were pretreated in the absence (-PTX) or presence (+PTX) of 100 ng/mL pertussis toxin 
overnight, then treated with UDP-Glc for 15 min.  C)  Cells were incubated with varying 
concentrations of UDP-Glc for 15 min.  Phospho-ERK1/2 and ERK1/2 were quantified 
using Scion Image software (Frederick, MD) and graphed using GraphPad Prism software 
(San Diego, CA).  Each phospho-ERK1/2 lane was normalized to the corresponding 
ERK1/2 control and plotted as fold stimulation over control.  Data shown are the average ± 
SE of four independent experiments.  D)  P2Y14-HEK293 cells were treated with either 0.2 
M sorbitol, 0.01 mg/mL anisomycin, or 100 µM UDP-Glc for the indicated times.  
Phospho-p38, phospho-JNK, total p38, and total JNK were determined as described in 
Methods.      
 
  
118
Figure 20.  UDP-Glc-promoted activation of MAP kinase activation in differentiated 
HL-60 cells.  A)  Wild-type or differentiated (see Methods) HL-60 cells were serum-
starved for 18 h prior to addition of 100 µM UDP-Glc and incubation continued for the 
indicated times.  Western blots for phospho-ERK1/2 and ERK1/2 were generated as 
described in Methods.  Phospho-ERK1/2 was quantified using Scion Image software 
(Frederick, MD) and graphed using GraphPad Prism software (San Diego, CA).  Each 
phospho-ERK1/2 lane was normalized to the corresponding ERK1/2 control and plotted 
as fold stimulation over control.  Data shown are the mean ± SE of six independent 
experiments (*p < 0.02).  B)  Serum-starved, differentiated HL-60 cells were incubated 
with 1 µM formyl-Met-Leu-Phe for the indicated times, and lysates were analyzed as 
described in Methods.  C)  Differentiated HL-60 cells were treated in the absence (-PTX) 
or presence (+PTX) of 200 ng/mL pertussis toxin for 4 h prior to assay.  Cells were 
incubated for the indicated times with 100 µM UDP-Glc and phospho-ERK1/2 and total 
ERK1/2 was quantified as described in Methods.   
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Chapter V.  Conclusions 
Ligand development studies have met with considerable success for the P2Y1-R and 
P2Y12-R, and we have applied a structure-activity relationship approach to develop 
ligands for the P2Y14-R.  Additionally, molecular modeling studies have been useful in 
guiding these studies.  Our studies on the P2Y14-R are focused on developing high 
affinity, selective, and non-hydrolyzable agonists and antagonists.  These studies, 
reviewed in Chapter 2, have yielded several novel agonists at the P2Y14-R, including 2-
thio-UDP-Glc, an agonist that exhibits six-fold greater potency than UDP-Glc (Ko et al., 
2007).  Molecular modeling studies have aided our conceptualization of the P2Y14-R 
tertiary structure (Ivanov et al., 2007), and guided a methodical analysis of the parameters 
of the ligand pharmacophore.  Identification of the hexose moiety of UDP-Glc as a fertile 
region for modification leads to a newly focused approach for future development of 
ligands.  Ongoing studies are aimed toward producing pharmacological tools that will be 
useful in further characterization of the P2Y14-R.  A high affinity, selective radioligand 
would be useful for binding assays, while a fluorophore-conjugated ligand could be 
useful for monitoring receptor expression and localization with microscopy.   
As a result of our ligand development studies, it is clear that most UDP-sugars 
activate the P2Y14-R (Ko et al., 2009).  Release of UDP-Glc from cells has been 
established (Lazarowski et al., 2003; Kreda et al., 2007; Kreda et al., 2008) and it is likely 
that other UDP-sugars are released from cells as well.  Our finding that other UDP-
sugars, in addition to the originally identified four, are agonists at the P2Y14-R 
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necessitates our re-thinking the profile of cognate agonists for the P2Y14-R and 
specifically, we must consider the possibility that the P2Y14-R has many cognate 
agonists.  Most UDP-sugars are equipotent at the P2Y14-R and so could theoretically 
activate the receptor in place of UDP-Glc.  Depending on the extracellular environment at 
the site of P2Y14-R expression, one or more UDP-sugars may activate the P2Y14-R 
endogenously.     
The P2Y14-R was classified as a P2Y12-like receptor based on sequence homology, 
and has been suspected to couple to the Gi family of G proteins, as does the P2Y12-R.  
With the work presented in Chapter 4, we unambiguously established that the P2Y14-R 
couples to inhibition of adenylyl cyclase stimulation, and to ERK1/2 phosphorylation, in 
an agonist-dependent and pertussis toxin-sensitive manner (Fricks et al., submitted).  
While the inhibition of adenylyl cyclase activity is likely to occur through Gi activation, 
the signaling from Gi-coupled receptors to activate MAPK is not well delineated, 
although previous evidence suggests that it may be dependent on Gβγ.  Both Gαi subunits 
and Gβγ dimers released from activated Gi have been reported to activate ERK1/2 
through several distinct mechanisms, however the mechanism by which P2Y14-R couples 
to ERK1/2 phosphorylation is unknown.   
Two mechanisms for Gi-dependent activation of ERK1/2 have been proposed.  Gαi2 
was reported to interact directly with Rap-1-GAP, suggesting that activated Gαi2 would 
lead to inactive Rap-1 (Pace et al., 1995; Mochizuki et al., 1999).  Because active Rap-1 
sequesters C-Raf away from Ras, alleviation of the Rap/Raf interaction would allow Raf 
to interact with Ras and consequently activate MAPK signaling downstream.  Another 
model of Gi stimulation of ERK1/2 implicates signaling downstream of adenylyl cyclase.  
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Upon inhibition of adenylyl cyclase, PKA activation concomitantly decreases, resulting 
in alleviation of PKA inhibition of C-Raf (Tang and Gilman, 1992; Radhika and 
Dhanasekaran, 2001).  Raf is then free to interact with Ras and activate the MAPK 
cascade. 
Evidence for Gβγ-dependent activation of MAPK has been reported for multiple Gi-
coupled GPCRs, including the M2 muscarinic receptor (Lopez-Ilasaca et al., 1997).  The 
β1-adrenergic receptor also is reported to activate MAPK through a Gβγ-dependent 
mechanism that is partially sensitive to pertussis toxin (Galandrin et al., 2008).  Each of 
the proposed signaling pathways converges on Ras, although the intermediates appear to 
be different depending on the receptor.  Recombinant α2A-adrenergic receptors in 
HEK293 cells and COS-7 cells have been suggested to use a pathway involving PLCβ 
and the intracellular calcium-activated Pyk2 kinase, which would activate Src, bringing 
together the Ras-activating complex Shc and SOS (Della Rocca et al., 1997).  A second, 
distinct pathway involving phosphatidyl-inositol-3-kinase (PI3K) is implicated in 
activation of ERK1/2 by LPA and thrombin receptors.  This model predicts that PI3K 
activates a not yet identified tyrosine kinase, which would, in turn, promote formation of 
the Ras-activating complex dynamin II/ Grb2/ SOS (Kranenburg et al., 1997; Kranenburg 
et al., 1999; Wunderlich et al., 1999).  The potential for the P2Y14-R to use one or more 
of these signaling pathways to activate ERK1/2 could be explored with the use of the 
Gβγ-sequestering carboxyl tail of β-adrenergic receptor kinase (β-ARK) (Inglese et al., 
1994) to determine whether the βγ dimer is necessary for MAPK signaling.  Further 
studies could utilize pharmacological inhibitors of protein intermediates to identify which 
proteins are involved in the P2Y14-R-dependent activation of MAPK. 
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Alternatively to signals downstream of the G protein, the involvement of β-arrestins 
in agonist-dependent transduction to MAPK cascades has been reported for some 
GPCRs.  In addition to their role in mediating endocytosis of ligand-bound receptor, β-
arrestins also act as scaffolding proteins that link some GPCRs, such as the β2-adrenergic 
receptor, to MAPK cascades (Luttrell et al., 1999).  In the proposed model, β-arrestin 
scaffolds the ligand-bound receptor in a complex with the tyrosine kinase Src, 
subsequently activating Ras-mediated MAPK cascades.  The β-arrestins have also been 
proposed to act as a scaffold protein for the complex associating Raf, MEK1, and ERK 
(DeFea et al., 2000; Luttrell et al., 2001).  While the β-arrestin mechanism of GPCR-
induced MAPK signaling has been described for few GPCRs, the array of possible 
pathways to determine the mechanism of P2Y14-R-dependent MAPK activation will 
require extensive investigation.         
In addition to the tissue specific Gαt, Gαz, and Gαgust, the Gi family of proteins 
includes Gαi1, Gαi2, Gαi3, and Gαo.  Which Gi proteins may be preferred by the P2Y14-R 
will be a topic of future study.  Indeed which Gi isoform couples to P2Y14-R may be 
dependent on the cell or tissue type, and relative expression of each of the Gi proteins.  
Functional studies in cells lacking each of the Gα subunits, such as with siRNA or from 
knockout mouse-derived cells, may provide some insight as to which of the Gi proteins 
the P2Y14-R may couple.    
The possibility that the P2Y14-R couples to other Gi or Gβγ signaling pathways such 
as ion channels, phospholipases, protein kinases, and receptor tyrosine kinases is a viable 
hypothesis, and awaits further investigation.  There are many proteins reported to interact 
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with Gβγ, and the potential for P2Y14-R to activate signaling pathways through Gβγ has 
not been explored.   
Another observation reported in Chapter 4 was that the natively expressed P2Y14-R 
does not couple to inhibition of adenylyl cyclase in differentiated HL-60 cells.  
Differentiated HL-60 cells are a cell model system frequently used to study neutrophil 
biology, and inhibition of adenylyl cyclase by GPCRs has not been unequivocally 
demonstrated in neutrophils nor in HL-60 cells, despite the abundant expression of Gi in 
both cell types.  Moreover, the Gi-coupled chemoattractant receptor FPR coupled to 
activation of adenylyl cyclase in neutrophils (Mahadeo et al., 2007).  Adenylyl cyclases I, 
V, and VI are the primary isoforms capable of inhibition by Gi (Watts and Neve, 2005).  
Neutrophils have been reported to express only adenylyl cyclases III, IV, VII and IX 
(Mahadeo et al., 2007), and therefore one would not expect to observe inhibition of 
adenylyl cyclase in neutrophils.  It is likely that Gi-coupled receptors such as the P2Y14-R 
have a unique signaling profile in this specialized cell type, and while we have 
established that the P2Y14-R couples to ERK1/2 phosphorylation in differentiated HL-60 
cells, it is possible that other signaling processes also are activated by the P2Y14-R.  More 
detailed signal transduction studies using differentiated HL-60 cells will delineate the 
signaling pathways activated by the P2Y14-R, and may reflect a potential function for the 
P2Y14-R in neutrophils. 
In addition to studies of signal transduction, the HL-60 cell model also will be a 
useful means for studies of P2Y14-R-regulated biology.  Expression of P2Y14-R mRNA 
has been demonstrated in neutrophils, but HL-60 cells have technical advantages over 
neutrophils.  Many of the GPCRs that are expressed on neutrophils are Gi-coupled 
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chemokine receptors that regulate immune responses such as chemotaxis.  Studies of 
UDP-Glc-dependent cellular processes in differentiated HL-60 cells may lead to 
elucidation of a P2Y14-R function in immune cells.  
The cell models developed for studies of the P2Y14-R will circumvent problems with 
the previously used cell system in which the P2Y14-R was coupled to the chimeric Gq/i.  
In previous studies, receptor-dependent signaling was observed in the absence of agonist.  
This phenomenon appeared to be somewhat dependent on agonist in the medium on the 
cultured cells because treatment of the cells with UDP-sugar hydrolyzing enzymes, such 
as E-NPP or UDP-Glc pyrophosphorylase reduced such activity.  However, a residual 
component of the activation in the absence of agonist could not be explained by the 
presence of agonist in the medium. In the cell lines stably expressing the P2Y14-R, there 
is no evidence of receptor activity in the absence of added agonist.  Upon measuring 
accumulation of cAMP, treatment of the cells with pertussis toxin would be expected to 
significantly increase the forskolin-stimulated level of cAMP if the receptor were 
constitutively active, because pertussis toxin would prevent Gi activation.  Results from 
such experiments indicate that the level of forskolin stimulation is similar in cells treated 
with pertussis toxin to those without.   
Another fallacy of the system using Gq/i became clear with recent studies of UDP.  In 
Chapter 3, I described the identification of UDP as a competitive antagonist at the P2Y14-
R (Fricks et al., 2008), and additional investigations in which the basal activity of the 
P2Y14-R was reduced with co-expression of E-NPP1 revealed that UDP is in fact, a 
partial agonist in this experimental system.  With the development of a robust cellular 
assay for assessing P2Y14-R signaling through its cognate G protein, Gi, as described in 
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Chapter 4, we have begun to characterize P2Y14-R function via its native signaling 
processes.  In contrast to the results in COS-7 cells in which the P2Y14-R and Gq/i were 
co-expressed, when UDP was studied in a cellular system in which the P2Y14-R coupled 
to its native G protein, UDP exhibited the efficacy of a full agonist, indicating that the 
Gq/i chimera may not be the ideal system for characterizing native P2Y14-R function. 
In multiple types of mammalian cells stably expressing the P2Y14-R, UDP exhibited 
agonist activity in assays measuring inhibition of forskolin-stimulated adenylyl cyclase.  
This was a surprising finding given that no other lab has reported agonist action of UDP 
at the P2Y14-R despite screens of nucleotides for agonism in many different experimental 
systems.  Results showing that the effect of UDP is P2Y14-R-dependent and pertussis 
toxin-sensitive will be detailed in a paper soon to be submitted for publication (Carter, 
Fricks, et al.). 
The reason for the seemingly differential action of UDP at the P2Y14-R in the two 
experimental systems is not immediately clear.  The simplest explanation is that the 
activation state of the receptor is slightly perturbed when coupled to Gq/i, such that it is 
capable of binding UDP.  However, activation of the G protein is not maximal.  Indeed 
UDP appears to have some partial agonist activity in the transfected system, but it also 
acts to block binding of UDP-Glc, and so appears to be a competitive antagonist.   
Interestingly, in parallel studies of the rat P2Y14-R coexpressed with Gq/i in COS-7 
cells, UDP was a full agonist.  The rat and human P2Y14-R share 80% amino acid 
sequence homology, and by extrapolation, also would be expected to have similar 
structural features.  Despite their similarities, the prospect of the rat P2Y14-R coupling to 
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Gq/i with a different orientation than the human P2Y14-R, and thus, permitting activation 
by UDP, is a distinct possibility.  
Studies of the β1 Adrenergic receptor suggest that different ligands can promote 
different conformation states of the receptor and in so doing, engage distinct signaling 
pathways (Galandrin et al., 2008).  In effect, it is likely that for some GPCRs, the 
receptor conformation attained with a particular ligand dictates the receptor’s G protein 
selectivity, or possibly alters the efficiencies of receptor coupling to various G proteins.  
Juxtaposed with the idea of ligand-induced receptor conformations, the availability of 
particular G proteins as the determining factor for relative agonist selectivity of a receptor 
is an alternative explanation for the differential action of UDP on the P2Y14-R in separate 
cellular systems. 
While the Gq/i chimera has been used in studies of many Gi-coupled GPCR, the 
structure of the P2Y14-R may not be amenable to signaling through this engineered 
protein.  It is possible that the P2Y14-R is in a partially activated state when co-expressed 
with Gq/i, and the activation not attributable to agonist in the medium is due to receptor 
that is in a partially active conformation.  An inverse agonist for the P2Y14-R would 
allow us to examine this possibility experimentally, but currently none is available. 
An altered receptor conformation would also explain the differences observed in UDP 
activity between the Gq/i system and the stable cell lines.  If the agonist binding pocket 
were oriented in such a way in the Gq/i system that UDP-Glc was accommodated but 
UDP was not, then it is easy to understand how UDP may appear as a partial 
agonist/antagonist.  When the P2Y14-R coupled to its native G protein, the receptor 
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binding pocket was potentially in a conformation that would permit UDP binding as an 
agonist and subsequently, UDP activation at the P2Y14-R.   
An alternative explanation implicates receptor expression as responsible for the 
dichotomous action of UDP in different cellular systems.  When increasing amounts of 
expression plasmid encoding the P2Y14-R are co-transfected with Gq/i, the apparent 
efficacy of UDP also increases to a level indicative of a partial agonist.  While we would 
expect that retroviral infection of cells would express receptor at levels close to that of an 
endogenous receptor, overexpression that introduced receptor reserve into the stable cell 
system would explain UDP’s action as an apparent full agonist.  Without a radioligand 
binding assay, however, we do not have the ability to quantify receptor in order to 
investigate such possibilities.        
With the finding that UDP is a P2Y14-R agonist, the relationship of P2Y14-R to the 
P2Y6-R must be addressed.  Just as the P2Y1-R and the P2Y12-R are co-expressed on 
platelets and have a cooperative function when activated by their shared agonist, ADP, to 
activate two distinct cellular signaling pathways, it is possible that the P2Y6-R and the 
P2Y14-R have a similarly important physiological role when co-expressed.  Selectively 
acting antagonists for each of these receptors may provide clues as to whether the P2Y6-R 
and P2Y14-R are functionally linked to any pathophysiological processes.  In cellular 
systems, the two receptors are commonly found expressed together.  Assays of UDP-
dependent activity in cells in which one of the receptors was knocked down by siRNA 
would aid our understanding of P2Y14-R versus P2Y6-R signaling.  Although the Gq and 
Gi pathways appear to be distinct, it is becoming more apparent that signaling networks 
cooperate to regulate some biological functions, and therapeutic development will be 
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forced to acknowledge the multiple regulatory mechanisms involved with treating any 
one disorder.  Just as with the P2Y1-R and P2Y12-R, we may find that the P2Y6-R and 
P2Y14-R signaling pathways converge to modulate some critical aspect of physiology. 
 Although much focus has been on the P2Y14-R as a potential immune cell modulator, 
the P2Y14-R likely has multiple specialized functions depending on the tissue type.  Just 
as the P2Y12-R is both a modulator of platelet aggregation and is involved in microglial 
migration (Haynes et al., 2006), so too may the P2Y14-R have distinct roles in the various 
tissues in which it is expressed.  In addition to immune cells, high expression levels for 
P2Y14-R mRNA have been reported in adipose tissue, placenta, brain and stomach. 
Recently, an effect of UDP-Glc on smooth muscle contractility was observed in the 
forestomach of mouse (Bassil et al., 2009).  In the same study, a knockout mouse in 
which the P2Y14-R gene was deleted was generated.  Adult P2Y14-R-/- mice were 
compared to wild type mice and UDP-Glc did not induce contractions in the stomachs of 
P2Y14-R KO mice, suggesting that the effect of UDP-Glc was P2Y14-R-dependent.  Thus, 
P2Y14-R expressed in stomach may have a role in gastric motility.   
While a normal phenotype was reported for the knockout mouse, no investigation of 
immune system physiology was described.  It would seem from this report of the 
knockout mouse that the P2Y14-R does not have a critical role in development or viability 
of mice, and may either have a redundant function in mouse, or function as part of a 
response mechanism, which will only be revealed after some primary insult such as 
bacterial infection or tissue damage.  Demonstration of P2Y14-R mRNA upregulation in 
rat brain after immunologic challenge (Moore et al., 2003) supports the notion that the 
P2Y14-R may be important in an organism’s response to injury or disease state.    
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The physiological relevance of the P2Y14-R remains elusive, but the work presented 
here advances us toward the common goal of understanding the function of the P2Y14-R.  
The coupling of the P2Y14-R to two signal transduction pathways, inhibition of adenylyl 
cyclase and activation of ERK1/2, was established.  Progress was made toward 
developing pharmacological tools that will advance our understanding of P2Y14-R 
function.  The cell models that were developed will be crucial for investigations of signal 
transduction and cell biological functions attributable to the P2Y14-R.  As we have no 
hint of a physiological function for the P2Y14-R from the knockout mouse, we will 
continue our progress toward characterization of the P2Y14-R even as we continue to 
develop better tools to make such efforts more accurate, efficient, and relevant. 
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